Slot System
Featured Buckets
Featured Buckets Admin
Reverse Chronological Sort
Allow Teaser Image

Enlarging Nodule on the Nipple

Article Type
Changed
Tue, 09/10/2019 - 15:32
Display Headline
Enlarging Nodule on the Nipple

The Diagnosis: Nipple Adenoma (Florid Papillomatosis of the Nipple) 

Biopsy of the nodule showed florid papillary hyperplasia of the ductal epithelium within the dermis that was sharply demarcated from the background stroma (Figure, A and B). Neither cytological nor architectural atypia were evident. There was no notable necrosis (Figure C). There was a background of fibrosis whereby the glandular ductal structures assumed a somewhat irregular growth pattern within the dermis with attendant hemorrhage. The patient underwent complete excision of the lesion. No evidence of carcinoma was seen on the final pathology, and the final margins were negative. 

Nipple adenoma. A, Proliferation of ducts within the dermis (H&E, original magnification ×10). B, Ducts are lined by papillary epithelium (H&E, original magnification ×20). C, Bland cytology and lack of concerning features such as necrosis (H&E, original magnification ×40)

First described in 1923 and fully characterized in 1955, nipple adenoma (also known as florid papillomatosis of the nipple) is a benign proliferative neoplasm that originates in the lactiferous ducts of the nipple.1,2 It most commonly affects women aged 40 to 50 years (range, 0-89 years); less than 5% of cases are reported in men.3,4 It predominantly is unilateral, with only rare cases of bilateral papillomatosis reported. Patients often present with serous or serosanguineous discharge and an itching or burning sensation. Symptoms may worsen with the menstrual cycle.4 On physical examination, it presents as an ill-defined red nodule on the nipple with crusting, erosion, or erythema of the nipple surface. Although imaging generally is not used to confirm the diagnosis, mammography should be performed prior to biopsy to rule out underlying breast pathology. Dermoscopy may show linear cherry red structures or red serpiginous and annular structures.5,6 The differential diagnosis of nipple adenoma includes Paget disease of the breast, adenomyoepithelioma, subareolar subsclerosing duct hyperplasia, syringomatous adenoma, adenosis tumor, low-grade adenosquamous carcinoma, low-grade ductal carcinoma in situ, tubular carcinoma, and sweat gland tumors.3  

Microscopic features of nipple adenoma have been categorized into 4 subtypes: sclerosing papillomatosis, papillomatosis, adenosis, and a mixed pattern.3,7 The tumors may have keratin cysts and focal necrosis but no atypia, and the myoepithelial cell layer is retained. Nipple adenomas show a glandular proliferation in the dermis that is relatively well circumscribed with glands that vary in appearance between a simple adenosislike pattern of growth to a papillary hyperplasia and/or usual ductal hyperplasia growth pattern. A pseudoinfiltrative pattern can occur when the glandular epithelium is entrapped within stromal fibrosis; however, the myoepithelial layer is retained. Occasionally, the glandular epithelium can grow in continuity with the surface squamous epithelium of the nipple, clinically simulating Paget disease of the breast.8 Immunohistochemical stains, specifically p63, p40, calponin 1, h-caldesmon, cytokeratin 5/6, CD10, and α; smooth muscle actin, highlight the myoepithelial cells, while cytokeratin 7 identifies the ductal epithelium, supporting the diagnosis.6 In addition to biopsy and microscopic tissue examination, touch preparation cytology, curettage cytology, and fine needle aspiration techniques have been used to perform cytologic examination of the lesions, aiding in identification of the benign or malignant nature of the neoplasm.6 Nipple adenoma also is referred to as florid papillomatosis of the nipple, papillary adenoma, erosive adenomatosis, and subareolar duct papillomatosis.

Although nipple adenoma is a benign tumor, up to 16.5% of affected patients had an ipsilateral or contralateral mammary carcinoma.9 The majority arose coincidentally but separately in the same breast, and carcinoma arose directly from the nipple adenoma in 8 cases; 3 cases were carcinomas that arose in men.10 A definitive association or causal relationship between nipple adenoma and subsequent development of breast cancer has not been identified, and the incidence of nipple adenoma in patients with a positive family history of breast cancer has not been examined. Therefore, although various treatments including cryosurgery, nipple splitting enucleation, and Mohs micrographic surgery have been proposed, complete excision remains the gold standard of therapy. Regular breast examinations and digital mammography are necessary to screen for local recurrences.  

References
  1. Miller E, Lewis D. The significance of serohemorrhagic or hemorrhagic discharge from the nipple. JAMA. 1923;81:1651-1657. 
  2. Jones DB. Florid papillomatosis of the nipple ducts. Cancer. 1955;8:315-319. 
  3. Rosen PP. Rosen's Breast Pathology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:120-128. 
  4. Brownstein MH, Phelps RG, Maqnin PH. Papillary adenoma of the nipple: analysis of fifteen new cases. J Am Acad Dermatol. 1985;12:707-715. 
  5. Takashima S, Fujita Y, Miyauchi T, et al. Dermoscopic observation in adenoma of the nipple. J Dermatol. 2015;42:341-342. 
  6. Spohn G, Trotter S, Tozbikian G, et al. Nipple adenoma in a female patient presenting with persistent erythema of the right nipple skin: case report, review of the literature, clinical implications, and relevancy to health care providers who evaluate and treat patients with dermatologic conditions of the breast skin. BMC Dermatol. 2016;16:4. 
  7. Shin SJ. Nipple adenoma (florid papillomatosis of the nipple). In: Dabbs DJ, ed. Breast Pathology. Philadelphia, PA: Elsevier Saunders; 2012:286-292.  
  8. Schnitt SJ, Collins LC. Biopsy Interpretation of the Breast. 2nd ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.  
  9. Salemis NS. Florid papillomatosis of the nipple: a rare presentation and review of the literature. Breast Dis. 2015;35:153-156.  
  10. Di Bonito M, Cantile M, Collina F, et al. Adenoma of the nipple: a clinicopathological report of 13 cases. Oncol Lett. 2014;7:1839-1842.
Article PDF
Author and Disclosure Information

From Weill Cornell Medicine, New York, New York. Drs. Waintraub and Lipner are from the Department of Dermatology, and Dr. Daniels is from the Department of Pathology.

The authors report no conflict of interest.

Correspondence: Shari R. Lipner, MD, PhD, 1305 York Ave, 9th Floor, New York, NY 10021 (shl9032@med.cornell.edu).

Issue
Cutis - 104(3)
Publications
Topics
Page Number
148, 155-156
Sections
Author and Disclosure Information

From Weill Cornell Medicine, New York, New York. Drs. Waintraub and Lipner are from the Department of Dermatology, and Dr. Daniels is from the Department of Pathology.

The authors report no conflict of interest.

Correspondence: Shari R. Lipner, MD, PhD, 1305 York Ave, 9th Floor, New York, NY 10021 (shl9032@med.cornell.edu).

Author and Disclosure Information

From Weill Cornell Medicine, New York, New York. Drs. Waintraub and Lipner are from the Department of Dermatology, and Dr. Daniels is from the Department of Pathology.

The authors report no conflict of interest.

Correspondence: Shari R. Lipner, MD, PhD, 1305 York Ave, 9th Floor, New York, NY 10021 (shl9032@med.cornell.edu).

Article PDF
Article PDF
Related Articles

The Diagnosis: Nipple Adenoma (Florid Papillomatosis of the Nipple) 

Biopsy of the nodule showed florid papillary hyperplasia of the ductal epithelium within the dermis that was sharply demarcated from the background stroma (Figure, A and B). Neither cytological nor architectural atypia were evident. There was no notable necrosis (Figure C). There was a background of fibrosis whereby the glandular ductal structures assumed a somewhat irregular growth pattern within the dermis with attendant hemorrhage. The patient underwent complete excision of the lesion. No evidence of carcinoma was seen on the final pathology, and the final margins were negative. 

Nipple adenoma. A, Proliferation of ducts within the dermis (H&E, original magnification ×10). B, Ducts are lined by papillary epithelium (H&E, original magnification ×20). C, Bland cytology and lack of concerning features such as necrosis (H&E, original magnification ×40)

First described in 1923 and fully characterized in 1955, nipple adenoma (also known as florid papillomatosis of the nipple) is a benign proliferative neoplasm that originates in the lactiferous ducts of the nipple.1,2 It most commonly affects women aged 40 to 50 years (range, 0-89 years); less than 5% of cases are reported in men.3,4 It predominantly is unilateral, with only rare cases of bilateral papillomatosis reported. Patients often present with serous or serosanguineous discharge and an itching or burning sensation. Symptoms may worsen with the menstrual cycle.4 On physical examination, it presents as an ill-defined red nodule on the nipple with crusting, erosion, or erythema of the nipple surface. Although imaging generally is not used to confirm the diagnosis, mammography should be performed prior to biopsy to rule out underlying breast pathology. Dermoscopy may show linear cherry red structures or red serpiginous and annular structures.5,6 The differential diagnosis of nipple adenoma includes Paget disease of the breast, adenomyoepithelioma, subareolar subsclerosing duct hyperplasia, syringomatous adenoma, adenosis tumor, low-grade adenosquamous carcinoma, low-grade ductal carcinoma in situ, tubular carcinoma, and sweat gland tumors.3  

Microscopic features of nipple adenoma have been categorized into 4 subtypes: sclerosing papillomatosis, papillomatosis, adenosis, and a mixed pattern.3,7 The tumors may have keratin cysts and focal necrosis but no atypia, and the myoepithelial cell layer is retained. Nipple adenomas show a glandular proliferation in the dermis that is relatively well circumscribed with glands that vary in appearance between a simple adenosislike pattern of growth to a papillary hyperplasia and/or usual ductal hyperplasia growth pattern. A pseudoinfiltrative pattern can occur when the glandular epithelium is entrapped within stromal fibrosis; however, the myoepithelial layer is retained. Occasionally, the glandular epithelium can grow in continuity with the surface squamous epithelium of the nipple, clinically simulating Paget disease of the breast.8 Immunohistochemical stains, specifically p63, p40, calponin 1, h-caldesmon, cytokeratin 5/6, CD10, and α; smooth muscle actin, highlight the myoepithelial cells, while cytokeratin 7 identifies the ductal epithelium, supporting the diagnosis.6 In addition to biopsy and microscopic tissue examination, touch preparation cytology, curettage cytology, and fine needle aspiration techniques have been used to perform cytologic examination of the lesions, aiding in identification of the benign or malignant nature of the neoplasm.6 Nipple adenoma also is referred to as florid papillomatosis of the nipple, papillary adenoma, erosive adenomatosis, and subareolar duct papillomatosis.

Although nipple adenoma is a benign tumor, up to 16.5% of affected patients had an ipsilateral or contralateral mammary carcinoma.9 The majority arose coincidentally but separately in the same breast, and carcinoma arose directly from the nipple adenoma in 8 cases; 3 cases were carcinomas that arose in men.10 A definitive association or causal relationship between nipple adenoma and subsequent development of breast cancer has not been identified, and the incidence of nipple adenoma in patients with a positive family history of breast cancer has not been examined. Therefore, although various treatments including cryosurgery, nipple splitting enucleation, and Mohs micrographic surgery have been proposed, complete excision remains the gold standard of therapy. Regular breast examinations and digital mammography are necessary to screen for local recurrences.  

The Diagnosis: Nipple Adenoma (Florid Papillomatosis of the Nipple) 

Biopsy of the nodule showed florid papillary hyperplasia of the ductal epithelium within the dermis that was sharply demarcated from the background stroma (Figure, A and B). Neither cytological nor architectural atypia were evident. There was no notable necrosis (Figure C). There was a background of fibrosis whereby the glandular ductal structures assumed a somewhat irregular growth pattern within the dermis with attendant hemorrhage. The patient underwent complete excision of the lesion. No evidence of carcinoma was seen on the final pathology, and the final margins were negative. 

Nipple adenoma. A, Proliferation of ducts within the dermis (H&E, original magnification ×10). B, Ducts are lined by papillary epithelium (H&E, original magnification ×20). C, Bland cytology and lack of concerning features such as necrosis (H&E, original magnification ×40)

First described in 1923 and fully characterized in 1955, nipple adenoma (also known as florid papillomatosis of the nipple) is a benign proliferative neoplasm that originates in the lactiferous ducts of the nipple.1,2 It most commonly affects women aged 40 to 50 years (range, 0-89 years); less than 5% of cases are reported in men.3,4 It predominantly is unilateral, with only rare cases of bilateral papillomatosis reported. Patients often present with serous or serosanguineous discharge and an itching or burning sensation. Symptoms may worsen with the menstrual cycle.4 On physical examination, it presents as an ill-defined red nodule on the nipple with crusting, erosion, or erythema of the nipple surface. Although imaging generally is not used to confirm the diagnosis, mammography should be performed prior to biopsy to rule out underlying breast pathology. Dermoscopy may show linear cherry red structures or red serpiginous and annular structures.5,6 The differential diagnosis of nipple adenoma includes Paget disease of the breast, adenomyoepithelioma, subareolar subsclerosing duct hyperplasia, syringomatous adenoma, adenosis tumor, low-grade adenosquamous carcinoma, low-grade ductal carcinoma in situ, tubular carcinoma, and sweat gland tumors.3  

Microscopic features of nipple adenoma have been categorized into 4 subtypes: sclerosing papillomatosis, papillomatosis, adenosis, and a mixed pattern.3,7 The tumors may have keratin cysts and focal necrosis but no atypia, and the myoepithelial cell layer is retained. Nipple adenomas show a glandular proliferation in the dermis that is relatively well circumscribed with glands that vary in appearance between a simple adenosislike pattern of growth to a papillary hyperplasia and/or usual ductal hyperplasia growth pattern. A pseudoinfiltrative pattern can occur when the glandular epithelium is entrapped within stromal fibrosis; however, the myoepithelial layer is retained. Occasionally, the glandular epithelium can grow in continuity with the surface squamous epithelium of the nipple, clinically simulating Paget disease of the breast.8 Immunohistochemical stains, specifically p63, p40, calponin 1, h-caldesmon, cytokeratin 5/6, CD10, and α; smooth muscle actin, highlight the myoepithelial cells, while cytokeratin 7 identifies the ductal epithelium, supporting the diagnosis.6 In addition to biopsy and microscopic tissue examination, touch preparation cytology, curettage cytology, and fine needle aspiration techniques have been used to perform cytologic examination of the lesions, aiding in identification of the benign or malignant nature of the neoplasm.6 Nipple adenoma also is referred to as florid papillomatosis of the nipple, papillary adenoma, erosive adenomatosis, and subareolar duct papillomatosis.

Although nipple adenoma is a benign tumor, up to 16.5% of affected patients had an ipsilateral or contralateral mammary carcinoma.9 The majority arose coincidentally but separately in the same breast, and carcinoma arose directly from the nipple adenoma in 8 cases; 3 cases were carcinomas that arose in men.10 A definitive association or causal relationship between nipple adenoma and subsequent development of breast cancer has not been identified, and the incidence of nipple adenoma in patients with a positive family history of breast cancer has not been examined. Therefore, although various treatments including cryosurgery, nipple splitting enucleation, and Mohs micrographic surgery have been proposed, complete excision remains the gold standard of therapy. Regular breast examinations and digital mammography are necessary to screen for local recurrences.  

References
  1. Miller E, Lewis D. The significance of serohemorrhagic or hemorrhagic discharge from the nipple. JAMA. 1923;81:1651-1657. 
  2. Jones DB. Florid papillomatosis of the nipple ducts. Cancer. 1955;8:315-319. 
  3. Rosen PP. Rosen's Breast Pathology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:120-128. 
  4. Brownstein MH, Phelps RG, Maqnin PH. Papillary adenoma of the nipple: analysis of fifteen new cases. J Am Acad Dermatol. 1985;12:707-715. 
  5. Takashima S, Fujita Y, Miyauchi T, et al. Dermoscopic observation in adenoma of the nipple. J Dermatol. 2015;42:341-342. 
  6. Spohn G, Trotter S, Tozbikian G, et al. Nipple adenoma in a female patient presenting with persistent erythema of the right nipple skin: case report, review of the literature, clinical implications, and relevancy to health care providers who evaluate and treat patients with dermatologic conditions of the breast skin. BMC Dermatol. 2016;16:4. 
  7. Shin SJ. Nipple adenoma (florid papillomatosis of the nipple). In: Dabbs DJ, ed. Breast Pathology. Philadelphia, PA: Elsevier Saunders; 2012:286-292.  
  8. Schnitt SJ, Collins LC. Biopsy Interpretation of the Breast. 2nd ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.  
  9. Salemis NS. Florid papillomatosis of the nipple: a rare presentation and review of the literature. Breast Dis. 2015;35:153-156.  
  10. Di Bonito M, Cantile M, Collina F, et al. Adenoma of the nipple: a clinicopathological report of 13 cases. Oncol Lett. 2014;7:1839-1842.
References
  1. Miller E, Lewis D. The significance of serohemorrhagic or hemorrhagic discharge from the nipple. JAMA. 1923;81:1651-1657. 
  2. Jones DB. Florid papillomatosis of the nipple ducts. Cancer. 1955;8:315-319. 
  3. Rosen PP. Rosen's Breast Pathology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:120-128. 
  4. Brownstein MH, Phelps RG, Maqnin PH. Papillary adenoma of the nipple: analysis of fifteen new cases. J Am Acad Dermatol. 1985;12:707-715. 
  5. Takashima S, Fujita Y, Miyauchi T, et al. Dermoscopic observation in adenoma of the nipple. J Dermatol. 2015;42:341-342. 
  6. Spohn G, Trotter S, Tozbikian G, et al. Nipple adenoma in a female patient presenting with persistent erythema of the right nipple skin: case report, review of the literature, clinical implications, and relevancy to health care providers who evaluate and treat patients with dermatologic conditions of the breast skin. BMC Dermatol. 2016;16:4. 
  7. Shin SJ. Nipple adenoma (florid papillomatosis of the nipple). In: Dabbs DJ, ed. Breast Pathology. Philadelphia, PA: Elsevier Saunders; 2012:286-292.  
  8. Schnitt SJ, Collins LC. Biopsy Interpretation of the Breast. 2nd ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.  
  9. Salemis NS. Florid papillomatosis of the nipple: a rare presentation and review of the literature. Breast Dis. 2015;35:153-156.  
  10. Di Bonito M, Cantile M, Collina F, et al. Adenoma of the nipple: a clinicopathological report of 13 cases. Oncol Lett. 2014;7:1839-1842.
Issue
Cutis - 104(3)
Issue
Cutis - 104(3)
Page Number
148, 155-156
Page Number
148, 155-156
Publications
Publications
Topics
Article Type
Display Headline
Enlarging Nodule on the Nipple
Display Headline
Enlarging Nodule on the Nipple
Sections
Questionnaire Body

A healthy 48-year-old woman presented with a growth on the right nipple that had been slowly enlarging over the last few months. She initially noticed mild swelling in the area that persisted and formed a soft lump. She described mild pain with intermittent drainage but no bleeding. Her medical history was unremarkable, including a negative personal and family history of breast and skin cancer. She was taking no medications prior to development of the mass. She had no recent history of pregnancy or breastfeeding. A mammogram and breast ultrasound were not concerning for carcinoma. Physical examination showed a soft, exophytic, mildly tender, pink nodule on the right nipple that measured 12.2×7 mm; no drainage, bleeding, or ulceration was present. The surrounding skin of the areola and breast demonstrated no clinical changes. The contralateral breast, areola, and nipple were unaffected. The patient had no appreciable axillary or cervical lymphadenopathy. A deep shave biopsy of the nodule was performed and sent for histopathologic examination. 

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 09/03/2019 - 11:30
Un-Gate On Date
Tue, 09/03/2019 - 11:30
Use ProPublica
CFC Schedule Remove Status
Tue, 09/03/2019 - 11:30
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

Violaceous Patches on the Arm

Article Type
Changed
Tue, 08/27/2019 - 12:43
Display Headline
Violaceous Patches on the Arm

The Diagnosis: Phacomatosis Cesioflammea  

Phacomatosis pigmentovascularis (PPV) encompasses a group of diseases that have a vascular nevus coupled with a pigmented nevus.1 It is divided into 5 types: Type I is defined by the presence of a vascular malformation and epidermal nevus; type II by a vascular malformation and dermal melanosis with or without nevus anemicus; type III by a vascular malformation and nevus spilus with or without nevus anemicus; type IV by a vascular malformation, dermal melanosis, and nevus spilus with or without nevus anemicus; and type V as cutis marmorata telangiectatica congenita and dermal melanosis.1  

Happle2 proposed a descriptive classification system in 2005 that eliminated type I PPV because neither linear epidermal nevus nor Becker nevus are derived from pigmentary cells. An appended "a" denotes a subtype with isolated cutaneous findings, while "b" is associated with extracutaneous manifestations. Phacomatosis cesioflammea (type IIa/b) refers to blue-hued dermal melanocytosis and nevus flammeus. Phacomatosis spilorosea (type IIIa/b) refers to nevus spilus and rose-colored nevus flammeus. Phacomatosis cesiomarmorata (type Va/b) refers to dermal melanocytosis and cutis marmorata telangiectasia congenita. The last group (type IVa/b) is unclassifiable phacomatosis pigmentovascularis.2,3  

Phacomatosis pigmentovascularis can be isolated to the skin or have associated extracutaneous findings, including ocular melanocytosis, seizures, or cognitive delay due to intracerebral vascular malformations. Patients also can develop limb and soft-tissue overgrowth.4 Phacomatosis pigmentovascularis has been found to be associated with mutations in the GNA11 and GNAQ genes. The theory behind PPV is twin spotting, resulting from a somatic mutation that leads to mosaic proliferation of 2 different cell lines.5 Phacomatosis pigmentovascularis can occur in isolation or can demonstrate the phenotype of Sturge-Weber syndrome or Klippel-Trenaunay syndrome. In Sturge-Weber syndrome, capillary malformations involve the face and underlying leptomeninges and cerebral cortex. Glaucoma and epilepsy also may be present. In Klippel-Trenaunay syndrome, capillary malformations involve the extremities (usually the legs) in association with varicose veins, soft-tissue hypertrophy, and skeletal overgrowth.6-9 Tuberous sclerosis is an autosomal-dominant neurocutaneous disease in which patients develop hamartomas throughout the body, including the brain, skin, eyes, kidneys, heart, and lungs. Cutaneous manifestations include facial angiofibromas, ungual fibromas, hypomelanotic macules (ash leaf spots, confetti-like lesions), shagreen patches or connective tissue hamartomas, and fibrous plaques on the forehead. Tuberous sclerosis does not include vascular malformations.10  

Our patient was diagnosed with PPV type IIb, or phacomatosis cesioflammea. He had a large port-wine stain involving the right upper arm, back (Figure, A), and chest (Figure, B) with involvement of the bilateral conjunctivae (Figure, C). Our case is unique because our patient did not have dermal melanocytosis, only ocular melanocytosis.  

Phacomatosis cesioflammea. A and B, Violaceous to red patches on the back and chest. C, Hyperpigmentation of the conjunctiva.

Once underlying neurologic and vascular anomalies have been ruled out, port-wine stains can be treated cosmetically. Pulsed dye laser is the gold standard therapy for capillary malformations, especially when instituted early. Follow-up with ophthalmology is advised to monitor ocular involvement. Shields et al11 suggested dilated fundoscopy for patients with port-wine stains because choroidal pigmentation often is the only ocular change seen. Ocular melanocytosis can progress to pigmented glaucoma or choroidal melanoma. 

References
  1. Fernandez-Guarino M, Boixeda P, De las Heras E, et al. Phakomatosis pigmentovascularis: clinical findings in 15 patients and review of the literature. J Am Acad Dermatol. 2008;58:88-93.  
  2. Happle R. Phacomatosis pigmentovascularis revisited and reclassified. Arch Dermatol. 2005;141:385-388. 
  3. Villarreal DJ, Leal F. Phacomatosis pigmentovascularis of cesioflammea type. An Bras Dermatol. 2016;91(5 suppl 1):54-56.  
  4. Thomas AC, Zeng Z, Riviere JB, et al. Mosaic activating mutations in GNA11 and GNAQ are associated with phakomatosis pigmentovascularis and extensive dermal melanocytosis. J Invest Dermatol. 2016;136:770-778. 
  5. Krema H, Simpson R, McGowan H. Choroidal melanoma in phacomatosis pigmentovascularis cesioflammea. Can J Ophthalmol. 2013;48:E41-E42. 
  6. Wu CY, Chen PH, Chen GS. Phacomatosis cesioflammea associated with pectus excavatum. Acta Derm Venereol. 2009;89:301-310.  
  7. Pradhan S, Patnaik S, Padhi T, et al. Phakomatosis pigmentovascularis type IIb, Sturge-Weber syndrome and cone shaped tongue: an unusual association. Indian J Dermatol Venereol Leprol. 2015;81:614-616.  
  8. Turk BG, Turkmen M, Tuna A, et al. Phakomatosis pigmentovascularis type IIb associated with Klippel-Trenaunay syndrome and congenital triangular alopecia. J Am Acad Dermatol. 2011;65:E46-E49. 
  9. Sen S, Bala S, Halder C, et al. Phakomatosis pigmentovascularis presenting with Sturge-Weber syndrome and Klippel-Trenaunay syndrome. Indian J Dermatol. 2015;60:77-79. 
  10. Schwartz RA, Fernandez G, Kotulska K, et al. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol. 2007;57:189-202.  
  11. Shields CL, Kligman BE, Suriano M, et al. Phacomatosis pigmentovascularis of cesioflammea type in 7 patients: combination of ocular pigmentation (melanocytosis or melanosis) and nevus flammeus with risk for melanoma. Arch Ophthalmol. 2011;129:746-750.  
Article PDF
Author and Disclosure Information

Dr. Le is from Hackensack Meridian Health Palisades Medical Center, North Bergen, New Jersey. Drs. Dyer and Miller are from Largo Medical Center, Florida.

The authors report no conflict of interest.

Correspondence: Cuong Le, DO, Hackensack Meridian Health Palisades Medical Center, Graduate Medical Education, 7600 River Rd, North Bergen, NJ 07047 (cuongles.09@gmail.com).

Issue
Cutis - 104(2)
Publications
Topics
Page Number
E25-E27
Sections
Author and Disclosure Information

Dr. Le is from Hackensack Meridian Health Palisades Medical Center, North Bergen, New Jersey. Drs. Dyer and Miller are from Largo Medical Center, Florida.

The authors report no conflict of interest.

Correspondence: Cuong Le, DO, Hackensack Meridian Health Palisades Medical Center, Graduate Medical Education, 7600 River Rd, North Bergen, NJ 07047 (cuongles.09@gmail.com).

Author and Disclosure Information

Dr. Le is from Hackensack Meridian Health Palisades Medical Center, North Bergen, New Jersey. Drs. Dyer and Miller are from Largo Medical Center, Florida.

The authors report no conflict of interest.

Correspondence: Cuong Le, DO, Hackensack Meridian Health Palisades Medical Center, Graduate Medical Education, 7600 River Rd, North Bergen, NJ 07047 (cuongles.09@gmail.com).

Article PDF
Article PDF
Related Articles

The Diagnosis: Phacomatosis Cesioflammea  

Phacomatosis pigmentovascularis (PPV) encompasses a group of diseases that have a vascular nevus coupled with a pigmented nevus.1 It is divided into 5 types: Type I is defined by the presence of a vascular malformation and epidermal nevus; type II by a vascular malformation and dermal melanosis with or without nevus anemicus; type III by a vascular malformation and nevus spilus with or without nevus anemicus; type IV by a vascular malformation, dermal melanosis, and nevus spilus with or without nevus anemicus; and type V as cutis marmorata telangiectatica congenita and dermal melanosis.1  

Happle2 proposed a descriptive classification system in 2005 that eliminated type I PPV because neither linear epidermal nevus nor Becker nevus are derived from pigmentary cells. An appended "a" denotes a subtype with isolated cutaneous findings, while "b" is associated with extracutaneous manifestations. Phacomatosis cesioflammea (type IIa/b) refers to blue-hued dermal melanocytosis and nevus flammeus. Phacomatosis spilorosea (type IIIa/b) refers to nevus spilus and rose-colored nevus flammeus. Phacomatosis cesiomarmorata (type Va/b) refers to dermal melanocytosis and cutis marmorata telangiectasia congenita. The last group (type IVa/b) is unclassifiable phacomatosis pigmentovascularis.2,3  

Phacomatosis pigmentovascularis can be isolated to the skin or have associated extracutaneous findings, including ocular melanocytosis, seizures, or cognitive delay due to intracerebral vascular malformations. Patients also can develop limb and soft-tissue overgrowth.4 Phacomatosis pigmentovascularis has been found to be associated with mutations in the GNA11 and GNAQ genes. The theory behind PPV is twin spotting, resulting from a somatic mutation that leads to mosaic proliferation of 2 different cell lines.5 Phacomatosis pigmentovascularis can occur in isolation or can demonstrate the phenotype of Sturge-Weber syndrome or Klippel-Trenaunay syndrome. In Sturge-Weber syndrome, capillary malformations involve the face and underlying leptomeninges and cerebral cortex. Glaucoma and epilepsy also may be present. In Klippel-Trenaunay syndrome, capillary malformations involve the extremities (usually the legs) in association with varicose veins, soft-tissue hypertrophy, and skeletal overgrowth.6-9 Tuberous sclerosis is an autosomal-dominant neurocutaneous disease in which patients develop hamartomas throughout the body, including the brain, skin, eyes, kidneys, heart, and lungs. Cutaneous manifestations include facial angiofibromas, ungual fibromas, hypomelanotic macules (ash leaf spots, confetti-like lesions), shagreen patches or connective tissue hamartomas, and fibrous plaques on the forehead. Tuberous sclerosis does not include vascular malformations.10  

Our patient was diagnosed with PPV type IIb, or phacomatosis cesioflammea. He had a large port-wine stain involving the right upper arm, back (Figure, A), and chest (Figure, B) with involvement of the bilateral conjunctivae (Figure, C). Our case is unique because our patient did not have dermal melanocytosis, only ocular melanocytosis.  

Phacomatosis cesioflammea. A and B, Violaceous to red patches on the back and chest. C, Hyperpigmentation of the conjunctiva.

Once underlying neurologic and vascular anomalies have been ruled out, port-wine stains can be treated cosmetically. Pulsed dye laser is the gold standard therapy for capillary malformations, especially when instituted early. Follow-up with ophthalmology is advised to monitor ocular involvement. Shields et al11 suggested dilated fundoscopy for patients with port-wine stains because choroidal pigmentation often is the only ocular change seen. Ocular melanocytosis can progress to pigmented glaucoma or choroidal melanoma. 

The Diagnosis: Phacomatosis Cesioflammea  

Phacomatosis pigmentovascularis (PPV) encompasses a group of diseases that have a vascular nevus coupled with a pigmented nevus.1 It is divided into 5 types: Type I is defined by the presence of a vascular malformation and epidermal nevus; type II by a vascular malformation and dermal melanosis with or without nevus anemicus; type III by a vascular malformation and nevus spilus with or without nevus anemicus; type IV by a vascular malformation, dermal melanosis, and nevus spilus with or without nevus anemicus; and type V as cutis marmorata telangiectatica congenita and dermal melanosis.1  

Happle2 proposed a descriptive classification system in 2005 that eliminated type I PPV because neither linear epidermal nevus nor Becker nevus are derived from pigmentary cells. An appended "a" denotes a subtype with isolated cutaneous findings, while "b" is associated with extracutaneous manifestations. Phacomatosis cesioflammea (type IIa/b) refers to blue-hued dermal melanocytosis and nevus flammeus. Phacomatosis spilorosea (type IIIa/b) refers to nevus spilus and rose-colored nevus flammeus. Phacomatosis cesiomarmorata (type Va/b) refers to dermal melanocytosis and cutis marmorata telangiectasia congenita. The last group (type IVa/b) is unclassifiable phacomatosis pigmentovascularis.2,3  

Phacomatosis pigmentovascularis can be isolated to the skin or have associated extracutaneous findings, including ocular melanocytosis, seizures, or cognitive delay due to intracerebral vascular malformations. Patients also can develop limb and soft-tissue overgrowth.4 Phacomatosis pigmentovascularis has been found to be associated with mutations in the GNA11 and GNAQ genes. The theory behind PPV is twin spotting, resulting from a somatic mutation that leads to mosaic proliferation of 2 different cell lines.5 Phacomatosis pigmentovascularis can occur in isolation or can demonstrate the phenotype of Sturge-Weber syndrome or Klippel-Trenaunay syndrome. In Sturge-Weber syndrome, capillary malformations involve the face and underlying leptomeninges and cerebral cortex. Glaucoma and epilepsy also may be present. In Klippel-Trenaunay syndrome, capillary malformations involve the extremities (usually the legs) in association with varicose veins, soft-tissue hypertrophy, and skeletal overgrowth.6-9 Tuberous sclerosis is an autosomal-dominant neurocutaneous disease in which patients develop hamartomas throughout the body, including the brain, skin, eyes, kidneys, heart, and lungs. Cutaneous manifestations include facial angiofibromas, ungual fibromas, hypomelanotic macules (ash leaf spots, confetti-like lesions), shagreen patches or connective tissue hamartomas, and fibrous plaques on the forehead. Tuberous sclerosis does not include vascular malformations.10  

Our patient was diagnosed with PPV type IIb, or phacomatosis cesioflammea. He had a large port-wine stain involving the right upper arm, back (Figure, A), and chest (Figure, B) with involvement of the bilateral conjunctivae (Figure, C). Our case is unique because our patient did not have dermal melanocytosis, only ocular melanocytosis.  

Phacomatosis cesioflammea. A and B, Violaceous to red patches on the back and chest. C, Hyperpigmentation of the conjunctiva.

Once underlying neurologic and vascular anomalies have been ruled out, port-wine stains can be treated cosmetically. Pulsed dye laser is the gold standard therapy for capillary malformations, especially when instituted early. Follow-up with ophthalmology is advised to monitor ocular involvement. Shields et al11 suggested dilated fundoscopy for patients with port-wine stains because choroidal pigmentation often is the only ocular change seen. Ocular melanocytosis can progress to pigmented glaucoma or choroidal melanoma. 

References
  1. Fernandez-Guarino M, Boixeda P, De las Heras E, et al. Phakomatosis pigmentovascularis: clinical findings in 15 patients and review of the literature. J Am Acad Dermatol. 2008;58:88-93.  
  2. Happle R. Phacomatosis pigmentovascularis revisited and reclassified. Arch Dermatol. 2005;141:385-388. 
  3. Villarreal DJ, Leal F. Phacomatosis pigmentovascularis of cesioflammea type. An Bras Dermatol. 2016;91(5 suppl 1):54-56.  
  4. Thomas AC, Zeng Z, Riviere JB, et al. Mosaic activating mutations in GNA11 and GNAQ are associated with phakomatosis pigmentovascularis and extensive dermal melanocytosis. J Invest Dermatol. 2016;136:770-778. 
  5. Krema H, Simpson R, McGowan H. Choroidal melanoma in phacomatosis pigmentovascularis cesioflammea. Can J Ophthalmol. 2013;48:E41-E42. 
  6. Wu CY, Chen PH, Chen GS. Phacomatosis cesioflammea associated with pectus excavatum. Acta Derm Venereol. 2009;89:301-310.  
  7. Pradhan S, Patnaik S, Padhi T, et al. Phakomatosis pigmentovascularis type IIb, Sturge-Weber syndrome and cone shaped tongue: an unusual association. Indian J Dermatol Venereol Leprol. 2015;81:614-616.  
  8. Turk BG, Turkmen M, Tuna A, et al. Phakomatosis pigmentovascularis type IIb associated with Klippel-Trenaunay syndrome and congenital triangular alopecia. J Am Acad Dermatol. 2011;65:E46-E49. 
  9. Sen S, Bala S, Halder C, et al. Phakomatosis pigmentovascularis presenting with Sturge-Weber syndrome and Klippel-Trenaunay syndrome. Indian J Dermatol. 2015;60:77-79. 
  10. Schwartz RA, Fernandez G, Kotulska K, et al. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol. 2007;57:189-202.  
  11. Shields CL, Kligman BE, Suriano M, et al. Phacomatosis pigmentovascularis of cesioflammea type in 7 patients: combination of ocular pigmentation (melanocytosis or melanosis) and nevus flammeus with risk for melanoma. Arch Ophthalmol. 2011;129:746-750.  
References
  1. Fernandez-Guarino M, Boixeda P, De las Heras E, et al. Phakomatosis pigmentovascularis: clinical findings in 15 patients and review of the literature. J Am Acad Dermatol. 2008;58:88-93.  
  2. Happle R. Phacomatosis pigmentovascularis revisited and reclassified. Arch Dermatol. 2005;141:385-388. 
  3. Villarreal DJ, Leal F. Phacomatosis pigmentovascularis of cesioflammea type. An Bras Dermatol. 2016;91(5 suppl 1):54-56.  
  4. Thomas AC, Zeng Z, Riviere JB, et al. Mosaic activating mutations in GNA11 and GNAQ are associated with phakomatosis pigmentovascularis and extensive dermal melanocytosis. J Invest Dermatol. 2016;136:770-778. 
  5. Krema H, Simpson R, McGowan H. Choroidal melanoma in phacomatosis pigmentovascularis cesioflammea. Can J Ophthalmol. 2013;48:E41-E42. 
  6. Wu CY, Chen PH, Chen GS. Phacomatosis cesioflammea associated with pectus excavatum. Acta Derm Venereol. 2009;89:301-310.  
  7. Pradhan S, Patnaik S, Padhi T, et al. Phakomatosis pigmentovascularis type IIb, Sturge-Weber syndrome and cone shaped tongue: an unusual association. Indian J Dermatol Venereol Leprol. 2015;81:614-616.  
  8. Turk BG, Turkmen M, Tuna A, et al. Phakomatosis pigmentovascularis type IIb associated with Klippel-Trenaunay syndrome and congenital triangular alopecia. J Am Acad Dermatol. 2011;65:E46-E49. 
  9. Sen S, Bala S, Halder C, et al. Phakomatosis pigmentovascularis presenting with Sturge-Weber syndrome and Klippel-Trenaunay syndrome. Indian J Dermatol. 2015;60:77-79. 
  10. Schwartz RA, Fernandez G, Kotulska K, et al. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol. 2007;57:189-202.  
  11. Shields CL, Kligman BE, Suriano M, et al. Phacomatosis pigmentovascularis of cesioflammea type in 7 patients: combination of ocular pigmentation (melanocytosis or melanosis) and nevus flammeus with risk for melanoma. Arch Ophthalmol. 2011;129:746-750.  
Issue
Cutis - 104(2)
Issue
Cutis - 104(2)
Page Number
E25-E27
Page Number
E25-E27
Publications
Publications
Topics
Article Type
Display Headline
Violaceous Patches on the Arm
Display Headline
Violaceous Patches on the Arm
Sections
Questionnaire Body

A 55-year-old man presented with red-violet patches on the right arm and chest that had been present since birth. The patches were asymptomatic and stable in size and shape. He denied any personal or family history of glaucoma or epilepsy. Physical examination demonstrated nonblanchable, violaceous to red patches on the right arm, back, and chest. No thrills or bruits were appreciable, and the right and left arms were of equal circumference and length. Further examination revealed hyperpigmented patches on the bilateral conjunctivae. 

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 08/27/2019 - 11:15
Un-Gate On Date
Tue, 08/27/2019 - 11:15
Use ProPublica
CFC Schedule Remove Status
Tue, 08/27/2019 - 11:15
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

Erythematous Papules and Pustules on the Nose

Article Type
Changed
Tue, 08/20/2019 - 16:18
Display Headline
Erythematous Papules and Pustules on the Nose

The Diagnosis: Granulosis Rubra Nasi 

A history of prominent nasal sweating was later elicited and the patient was subsequently diagnosed with granulosis rubra nasi. She was instructed to continue daily use of topical pimecrolimus with the addition of topical atropine, resulting in complete resolution of the eruption at 6-week follow-up (Figure, A). She was then maintained on topical atropine monotherapy, only noting recurrence with cessation of the atropine (Figure, B).  

A, Complete clearance of granulosis rubra nasi at 6-week follow-up after using topical pimecrolimus and atropine once daily. B, Complete clearance 2 months later after using topical atropine monotherapy.

Other successful treatment regimens of granulosis rubra nasi include injection of botulinum toxin into the nose,1 monotherapy with topical tacrolimus,2 topical indomethacin, steroids, and cryotherapy, among other modalities.1 Topical atropine and pimecrolimus were selected as first-line agents for treating our pediatric patient due to tolerability and their anti-inflammatory and anticholinergic properties.  

Granulosis rubra nasi is a form of focal hyperhidrosis that presents as erythematous papules, pustules, and vesicles of the midface, especially the nose.3 It is a fairly rare condition that can mimic many other common clinical entities, including comedonal acne, nevus comedonicus, periorificial dermatitis, and tinea faciei, but is resistant to treatments aimed at these disorders. It was first described as a "peculiar disease of the skin of the nose in children" in a case report by Jadassohn4 in 1901. It is most common in children aged 7 to 12 years and typically resolves at puberty; adults rarely are affected. Although the etiology has not yet been elucidated, autosomal-dominant transmission has been described, and the cutaneous changes are hypothesized to be secondary to hyperhidrosis.5 This postulation is further corroborated by a case report of a pheochromocytoma-associated granulosis rubra nasi that resolved with surgical excision of the pheochromocytoma.6 It is not uncommon for patients to have concomitant palmoplantar hyperhidrosis and acrocyanosis.5 Histopathologic examination is not necessary for diagnosis, but when performed, it discloses a mononuclear cellular infiltrate surrounding eccrine sweat ducts, blood vessels, and lymphatics without other abnormalities of the epidermis or pilosebaceous unit.1-3,7 
 

References
  1. Grazziotin TC, Buffon RB, Da Silva Manzoni AP, et al. Treatment of granulosis rubra nasi with botulinum toxin. Dermatol Surg. 2009;35:1298-1299. 
  2. Kumar P, Gosai A, Mondal AK, et al. Granulosis rubra nasi: a rare condition treated successfully with topical tacrolimus. Dermatol Reports. 2012;4:E5. 
  3. Sargunam C, Thomas J, Ahmed NA. Granulosis rubra nasi. Indian Dermatol Online J. 2013;4:208-209. 
  4. Jadassohn J. Ueber eine eigenartige erkrankung der nasenhaut bei kindern. Arch Derm Syph. 1901;58:145-158. 
  5. Hellier FF. Granulosis rubra nasi in a mother and daughter. Br Med J. 1937;2:1068. 
  6. Heid E, Samain F, Jelen G, et al. Granulosis rubra nasi and pheochromocytoma. Ann Dermatol Venereol. 1996;123:106-108.  
  7. Akhdari N. Granulosis rubra nasi. Int J Dermatol. 2007;46:396. 
Article PDF
Author and Disclosure Information

From the Division of Dermatology, University of Texas Dell Medical School, Austin.

The authors report no conflict of interest.

Correspondence: Ashley D. Lundgren, MD, 313 E 12th St, Ste 103, Austin, TX 78701 (ashley.diana@gmail.com).

Issue
Cutis - 104(2)
Publications
Topics
Page Number
E10-E11
Sections
Author and Disclosure Information

From the Division of Dermatology, University of Texas Dell Medical School, Austin.

The authors report no conflict of interest.

Correspondence: Ashley D. Lundgren, MD, 313 E 12th St, Ste 103, Austin, TX 78701 (ashley.diana@gmail.com).

Author and Disclosure Information

From the Division of Dermatology, University of Texas Dell Medical School, Austin.

The authors report no conflict of interest.

Correspondence: Ashley D. Lundgren, MD, 313 E 12th St, Ste 103, Austin, TX 78701 (ashley.diana@gmail.com).

Article PDF
Article PDF
Related Articles

The Diagnosis: Granulosis Rubra Nasi 

A history of prominent nasal sweating was later elicited and the patient was subsequently diagnosed with granulosis rubra nasi. She was instructed to continue daily use of topical pimecrolimus with the addition of topical atropine, resulting in complete resolution of the eruption at 6-week follow-up (Figure, A). She was then maintained on topical atropine monotherapy, only noting recurrence with cessation of the atropine (Figure, B).  

A, Complete clearance of granulosis rubra nasi at 6-week follow-up after using topical pimecrolimus and atropine once daily. B, Complete clearance 2 months later after using topical atropine monotherapy.

Other successful treatment regimens of granulosis rubra nasi include injection of botulinum toxin into the nose,1 monotherapy with topical tacrolimus,2 topical indomethacin, steroids, and cryotherapy, among other modalities.1 Topical atropine and pimecrolimus were selected as first-line agents for treating our pediatric patient due to tolerability and their anti-inflammatory and anticholinergic properties.  

Granulosis rubra nasi is a form of focal hyperhidrosis that presents as erythematous papules, pustules, and vesicles of the midface, especially the nose.3 It is a fairly rare condition that can mimic many other common clinical entities, including comedonal acne, nevus comedonicus, periorificial dermatitis, and tinea faciei, but is resistant to treatments aimed at these disorders. It was first described as a "peculiar disease of the skin of the nose in children" in a case report by Jadassohn4 in 1901. It is most common in children aged 7 to 12 years and typically resolves at puberty; adults rarely are affected. Although the etiology has not yet been elucidated, autosomal-dominant transmission has been described, and the cutaneous changes are hypothesized to be secondary to hyperhidrosis.5 This postulation is further corroborated by a case report of a pheochromocytoma-associated granulosis rubra nasi that resolved with surgical excision of the pheochromocytoma.6 It is not uncommon for patients to have concomitant palmoplantar hyperhidrosis and acrocyanosis.5 Histopathologic examination is not necessary for diagnosis, but when performed, it discloses a mononuclear cellular infiltrate surrounding eccrine sweat ducts, blood vessels, and lymphatics without other abnormalities of the epidermis or pilosebaceous unit.1-3,7 
 

The Diagnosis: Granulosis Rubra Nasi 

A history of prominent nasal sweating was later elicited and the patient was subsequently diagnosed with granulosis rubra nasi. She was instructed to continue daily use of topical pimecrolimus with the addition of topical atropine, resulting in complete resolution of the eruption at 6-week follow-up (Figure, A). She was then maintained on topical atropine monotherapy, only noting recurrence with cessation of the atropine (Figure, B).  

A, Complete clearance of granulosis rubra nasi at 6-week follow-up after using topical pimecrolimus and atropine once daily. B, Complete clearance 2 months later after using topical atropine monotherapy.

Other successful treatment regimens of granulosis rubra nasi include injection of botulinum toxin into the nose,1 monotherapy with topical tacrolimus,2 topical indomethacin, steroids, and cryotherapy, among other modalities.1 Topical atropine and pimecrolimus were selected as first-line agents for treating our pediatric patient due to tolerability and their anti-inflammatory and anticholinergic properties.  

Granulosis rubra nasi is a form of focal hyperhidrosis that presents as erythematous papules, pustules, and vesicles of the midface, especially the nose.3 It is a fairly rare condition that can mimic many other common clinical entities, including comedonal acne, nevus comedonicus, periorificial dermatitis, and tinea faciei, but is resistant to treatments aimed at these disorders. It was first described as a "peculiar disease of the skin of the nose in children" in a case report by Jadassohn4 in 1901. It is most common in children aged 7 to 12 years and typically resolves at puberty; adults rarely are affected. Although the etiology has not yet been elucidated, autosomal-dominant transmission has been described, and the cutaneous changes are hypothesized to be secondary to hyperhidrosis.5 This postulation is further corroborated by a case report of a pheochromocytoma-associated granulosis rubra nasi that resolved with surgical excision of the pheochromocytoma.6 It is not uncommon for patients to have concomitant palmoplantar hyperhidrosis and acrocyanosis.5 Histopathologic examination is not necessary for diagnosis, but when performed, it discloses a mononuclear cellular infiltrate surrounding eccrine sweat ducts, blood vessels, and lymphatics without other abnormalities of the epidermis or pilosebaceous unit.1-3,7 
 

References
  1. Grazziotin TC, Buffon RB, Da Silva Manzoni AP, et al. Treatment of granulosis rubra nasi with botulinum toxin. Dermatol Surg. 2009;35:1298-1299. 
  2. Kumar P, Gosai A, Mondal AK, et al. Granulosis rubra nasi: a rare condition treated successfully with topical tacrolimus. Dermatol Reports. 2012;4:E5. 
  3. Sargunam C, Thomas J, Ahmed NA. Granulosis rubra nasi. Indian Dermatol Online J. 2013;4:208-209. 
  4. Jadassohn J. Ueber eine eigenartige erkrankung der nasenhaut bei kindern. Arch Derm Syph. 1901;58:145-158. 
  5. Hellier FF. Granulosis rubra nasi in a mother and daughter. Br Med J. 1937;2:1068. 
  6. Heid E, Samain F, Jelen G, et al. Granulosis rubra nasi and pheochromocytoma. Ann Dermatol Venereol. 1996;123:106-108.  
  7. Akhdari N. Granulosis rubra nasi. Int J Dermatol. 2007;46:396. 
References
  1. Grazziotin TC, Buffon RB, Da Silva Manzoni AP, et al. Treatment of granulosis rubra nasi with botulinum toxin. Dermatol Surg. 2009;35:1298-1299. 
  2. Kumar P, Gosai A, Mondal AK, et al. Granulosis rubra nasi: a rare condition treated successfully with topical tacrolimus. Dermatol Reports. 2012;4:E5. 
  3. Sargunam C, Thomas J, Ahmed NA. Granulosis rubra nasi. Indian Dermatol Online J. 2013;4:208-209. 
  4. Jadassohn J. Ueber eine eigenartige erkrankung der nasenhaut bei kindern. Arch Derm Syph. 1901;58:145-158. 
  5. Hellier FF. Granulosis rubra nasi in a mother and daughter. Br Med J. 1937;2:1068. 
  6. Heid E, Samain F, Jelen G, et al. Granulosis rubra nasi and pheochromocytoma. Ann Dermatol Venereol. 1996;123:106-108.  
  7. Akhdari N. Granulosis rubra nasi. Int J Dermatol. 2007;46:396. 
Issue
Cutis - 104(2)
Issue
Cutis - 104(2)
Page Number
E10-E11
Page Number
E10-E11
Publications
Publications
Topics
Article Type
Display Headline
Erythematous Papules and Pustules on the Nose
Display Headline
Erythematous Papules and Pustules on the Nose
Sections
Questionnaire Body

A healthy 9-year-old girl presented with a 2-year history of erythematous papules and pustules on the nose. There was no involvement of the rest of the face or body. At the time of presentation, she had been treated with several topical therapies including steroids, calcineurin inhibitors, antibiotics, and retinoids without improvement. A potassium hydroxide preparation from a pustule was performed and revealed only normal keratinocytes.

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 08/20/2019 - 15:15
Un-Gate On Date
Tue, 08/20/2019 - 15:15
Use ProPublica
CFC Schedule Remove Status
Tue, 08/20/2019 - 15:15
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

Well-Circumscribed Tumor on the Hand

Article Type
Changed
Thu, 08/15/2019 - 16:23
Display Headline
Well-Circumscribed Tumor on the Hand

The Diagnosis: Nodular Kaposi Sarcoma 

Epidemic Kaposi sarcoma (KS) primarily affects patients with human immunodeficiency virus (HIV) infection. Kaposi sarcoma can appear as brown, red, or blue-black macules, plaques, patches, nodules, or tumors, and it often is observed as multifocal cutaneous lesions located on the head, neck, and upper aspects of the trunk in a fulminant manner. Kaposi sarcoma portends a poor prognosis and is an AIDS-defining malignancy.1-3 Importantly, antiretroviral therapy does not preclude its consideration in those without AIDS-defining CD4 cell counts and undetectable HIV viremia presenting with cutaneous manifestations.2,3 A retrospective review by Daly et al4 reported KS lesions in patients with CD4 lymphocyte counts greater than 300 cells/µL, most of whom were antiretroviral therapy-naïve patients. Also, those with higher CD4 counts tended to have a solitary KS lesion at presentation, while those with CD4 counts less than 300 cells/µL tended to present with multiple foci.4 Epidemic KS lesions are clinically indistinguishable from other common cutaneous conditions in the differential diagnosis of KS, necessitating biopsy for histopathologic examination. Light microscopy findings help to delineate the diagnosis of KS. Immunohistochemical staining to the latent nuclear antigen 1 of human herpesvirus 8 (HHV-8) confirms the KS diagnosis.5,6 Our patient's presentation as a solitary acral lesion was atypical for KS.  

Light microscopy of our patient's biopsy demonstrated a large tumor on the acral surface of the right hand. Dermal collections of basophilic spindled cells clustered with small slitlike vascular spaces with abundant erythrocyte extravasation and numerous large ectatic vessels at the periphery were seen (Figure, A). At higher magnification, interlaced bundles of spindle cells with slitlike vessels with scattered lymphocytes and plasma cells were seen (Figure, B). An immunohistochemical stain for HHV-8 was positive and largely confined to spindle cells (Figure, C). These findings confirmed KS and met AIDS-defining criteria. Awareness of these histopathologic features is key in differentiating KS from other conditions in the differential diagnosis.  

Kaposi sarcoma. A, Dermal collection of basophilic spindled cells clustered with small slitlike vascular spaces with abundant erythrocyte extravasation and numerous large ectatic vessels at the periphery (H&E, original magnification ×40). B, Interlaced bundles of spindle cells with slitlike vessels with scattered lymphocytes and plasma cells (H&E, original magnification ×400). C, Immunohistochemical staining showed human herpesvirus 8 positivity largely confined to spindle cells (original magnification ×20).

The patient's history of late latent syphilis coinfected with HIV and persistently elevated rapid plasma reagin that was recalcitrant to therapy placed an atypical nodular presentation within reason for the differential diagnosis. Deviations from the typical papulosquamous presentation with acral involvement in an immunocompromised patient mandates a consideration for syphilis with an atypical presentation. Atypical presentations include nodular, annular, pustular, lues maligna, frambesiform, corymbose, and photosensitive distributions.7,8 Notably, coinfection with HIV modifies the clinical presentation, serology, and efficacy of treatment.7-10 Atypical presentations are more common in coinfected HIV-positive patients, mandating a high degree of suspicion. Nodular secondary syphilis and the noduloulcerative form (lues maligna) often spare the palmar and plantar surfaces, and patients often have constitutional symptoms accompanying the cutaneous eruptions. In questionable cases, a biopsy lends clarification. Light microscopy on hematoxylin and eosin (H&E) staining may display acanthosis, superficial and deep perivascular swelling, plasma, histiocyte infiltrates, dermoepidermal junction changes, mixed patterns, epidermal hyperplasia, and dermal vascular thickening.7-9,11 Spirochetes may be observed on Warthin-Starry stain; however, artifact obscuration from melanin granules and reticular fibers or paucity of organisms can make identification difficult. Immunohistochemical staining may prove useful when H&E stains are atypical or have a paucity of organisms or plasma cells or when silver stains have artifactual obscuration.9 Our patient's solitary palmar lesion without constitutional symptoms made an atypical nodular secondary syphilis presentation less likely. Ultimately, the histopathologic findings were consistent with KS.  

Bacillary angiomatosis (BA) is caused by Bartonella species and results in vascular proliferation with cutaneous manifestation. It frequently is observed in patients with HIV or other immunosuppressive conditions as well as patients with exposure to mammals or their vectors. Protean cutaneous manifestations and distributions of BA exist. The number of lesions can be singular to thousands. Solitary superficial pyogenic granuloma-like lesions can be clinically indistinguishable from both KS and pyogenic granuloma (PG). Superficial lesions often begin as red, violaceous, or flesh-colored papules that hemorrhage easily with trauma. The morphology of the papule can progress to be exophytic with dome-shaped or ulcerative surface features and is rubbery on palpation.12 Biopsy is required to differentiate BA from KS. Bacillary angiomatosis on light microscopy with H&E shows protuberant, lobulated, round vessels with plump endothelial cells with or without necrosis. A neutrophil infiltrate in close proximity to bacilli may be noted. Warthin-Starry stain demonstrates numerous bacilli juxtaposed to these endothelial cells. The lack of immunohistochemical staining for HHV-8 also differentiates BA from KS.12,13  

Pyogenic granuloma is resultant from proliferation of endothelial cells with a lobular architecture. Pyogenic granulomas are benign, rapidly progressive, acquired lesions presenting in the skin and mucous membranes. Pyogenic granuloma often presents as a single painless papule or nodule with a glistening red-violaceous color that occasionally appears with a perilesional collarette. The lesions are friable and easily hemorrhage. Pyogenic granuloma has been associated with local skin trauma and estrogen hormones. Histopathologic examination of PG assists with differentiation from other nodular lesions. Light microscopy with standard H&E staining demonstrates a network of capillaries arranged into a lobule surrounded by a fibrous matrix. Endothelial cells appear round and protrude into the vascular lamina. Mitotic activity is increased. Lack of findings on Warthin-Starry stain assists with differentiating PG from BA, while the microscopy architecture and immunohistochemical staining differentiates PG from KS.6,13,14 

Squamous cell carcinoma (SCC) is the primary malignant cancer of the hand. The dorsal aspect of the hand is the most common location; SCC less commonly is located on the palmar surface, fingers, nail bed, or intertriginous areas.15-17 Chakrabarti et al16 found that these lesions were invasive SCC when located on the palmar surface. Morphologically, SCC takes an exophytic papular, nodular, or scaly appearance with a red to flesh-colored appearance and poor demarcation of the borders. Progression to large ulcerated or secondarily infected lesions also can occur. The inflammatory reaction may cause tenderness to palpation and hemorrhage with trauma. Histopathologic examination of invasive SCC reveals atypical keratinocytes violating the basement membrane and abundant cytoplasm. Our patient's clinical presentation placed invasive SCC low on the differential diagnosis, and the histopathologic and immunohistochemical results eliminated SCC as the diagnosis. 

References
  1. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000;342:1027-1038.  
  2. Pipette WW. The incidence of second malignancies in subsets of Kaposi's sarcoma. J Am Acad Dermatol. 1987;16:855-861. 
  3. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS. 2017;12:6-11.  
  4. Daly ML, Fogo A, McDonald C, et al. Kaposi sarcoma: no longer an AIDS-defining illness? a retrospective study of Kaposi sarcoma cases with CD4 counts above 300/mm³ at presentation. Clin Exp Dermatol. 2014;39:7-12. 
  5. Broccolo F, Tassan Din C, Viganò MG, et al. HHV-8 DNA replication correlates with the clinical status in AIDS-related Kaposi's sarcoma. J Clin Virol. 2016;78:47-52. 
  6. Pereira PF, Cuzzi T, Galhardo MC. Immunohistochemical detection of the latent nuclear antigen-1 of the human herpesvirus type 8 to differentiate cutaneous epidemic Kaposi sarcoma and its histological simulators. An Bras Dermatol. 2013;88:243-246. 
  7. Gevorgyan O, Owen BD, Balavenkataraman A, et al. A nodular-ulcerative form of secondary syphilis in AIDS. Proc (Bayl Univ Med Cent). 2017;30:80-82. 
  8. Balagula Y, Mattei PL, Wisco OJ, et al. The great imitator revisited: the spectrum of atypical cutaneous manifestations of secondary syphilis. Int J Dermatol. 2014;53:1434-1441. 
  9. Hoang MP, High WA, Molberg KH. Secondary syphilis: a histologic and immunohistochemical evaluation. J Cutan Pathol. 2004;31:595-599. 
  10. Yayli S, della Torre R, Hegyi I, et al. Late secondary syphilis with nodular lesions mimicking Kaposi sarcoma in a patient with human immunodeficiency virus. Int J Dermatol. 2014;53:E71-E73. 
  11. Jeerapaet P, Ackerman AB. Histologic patterns of secondary syphilis. Arch Dermatol. 1973;107:373-377. 
  12. Cockerell CJ, LeBoit PE. Bacillary angiomatosis: a newly characterized, pseudoneoplastic, infectious, cutaneous vascular disorder. J Am Acad Dermatol. 1990;22:501-512.  
  13. Forrestel AK, Naujokas A, Martin JN, et al. Bacillary angiomatosis masquerading as Kaposi's sarcoma in East Africa. J Int Assoc Provid AIDS Care. 2015;14:21-25. 
  14. Fortna RR, Junkins-Hopkins JM. A case of lobular capillary hemangioma (pyogenic granuloma), localized to the subcutaneous tissue, and a review of the literature. Am J Dermatopathol. 2007;29:408-411. 
  15. Marks R. Squamous cell carcinoma. Lancet. 1996;347:735-738.  
  16. Chakrabarti I, Watson JD, Dorrance H. Skin tumours of the hand. a 10-year review. J Hand Surg Br. 1993;18:484-486. 
  17. Sobanko JF, Dagum AB, Davis IC, et al. Soft tissue tumors of the hand. 2. malignant. Dermatol Surg. 2007;33:771-785. 
Article PDF
Author and Disclosure Information

Dr. Linabury was from the US Navy Department of Medicine, Falls Church, Virginia, and currently is from the Department of Dermatology, Naval Medical Center San Diego, California. Dr. Roman was from the Dermatology Department, Walter Reed National Military Medical Center, Bethesda, Maryland, and currently is from the Dermatology Department, Portsmouth Naval Medical Center, Virginia.

The authors report no conflict of interest.

The views expressed in this article reflect the results of research conducted by the authors and do not necessarily reflect the official policy or position of the US Department of the Navy, Department of Defense, or the US Government.

Correspondence: John F. Linabury, DO, Naval Medical Center San Diego, 34800 Bob Wilson Dr, San Diego, CA 92134 (johnflinabury@gmail.com).

Issue
Cutis - 104(2)
Publications
Topics
Page Number
E4-E6
Sections
Author and Disclosure Information

Dr. Linabury was from the US Navy Department of Medicine, Falls Church, Virginia, and currently is from the Department of Dermatology, Naval Medical Center San Diego, California. Dr. Roman was from the Dermatology Department, Walter Reed National Military Medical Center, Bethesda, Maryland, and currently is from the Dermatology Department, Portsmouth Naval Medical Center, Virginia.

The authors report no conflict of interest.

The views expressed in this article reflect the results of research conducted by the authors and do not necessarily reflect the official policy or position of the US Department of the Navy, Department of Defense, or the US Government.

Correspondence: John F. Linabury, DO, Naval Medical Center San Diego, 34800 Bob Wilson Dr, San Diego, CA 92134 (johnflinabury@gmail.com).

Author and Disclosure Information

Dr. Linabury was from the US Navy Department of Medicine, Falls Church, Virginia, and currently is from the Department of Dermatology, Naval Medical Center San Diego, California. Dr. Roman was from the Dermatology Department, Walter Reed National Military Medical Center, Bethesda, Maryland, and currently is from the Dermatology Department, Portsmouth Naval Medical Center, Virginia.

The authors report no conflict of interest.

The views expressed in this article reflect the results of research conducted by the authors and do not necessarily reflect the official policy or position of the US Department of the Navy, Department of Defense, or the US Government.

Correspondence: John F. Linabury, DO, Naval Medical Center San Diego, 34800 Bob Wilson Dr, San Diego, CA 92134 (johnflinabury@gmail.com).

Article PDF
Article PDF
Related Articles

The Diagnosis: Nodular Kaposi Sarcoma 

Epidemic Kaposi sarcoma (KS) primarily affects patients with human immunodeficiency virus (HIV) infection. Kaposi sarcoma can appear as brown, red, or blue-black macules, plaques, patches, nodules, or tumors, and it often is observed as multifocal cutaneous lesions located on the head, neck, and upper aspects of the trunk in a fulminant manner. Kaposi sarcoma portends a poor prognosis and is an AIDS-defining malignancy.1-3 Importantly, antiretroviral therapy does not preclude its consideration in those without AIDS-defining CD4 cell counts and undetectable HIV viremia presenting with cutaneous manifestations.2,3 A retrospective review by Daly et al4 reported KS lesions in patients with CD4 lymphocyte counts greater than 300 cells/µL, most of whom were antiretroviral therapy-naïve patients. Also, those with higher CD4 counts tended to have a solitary KS lesion at presentation, while those with CD4 counts less than 300 cells/µL tended to present with multiple foci.4 Epidemic KS lesions are clinically indistinguishable from other common cutaneous conditions in the differential diagnosis of KS, necessitating biopsy for histopathologic examination. Light microscopy findings help to delineate the diagnosis of KS. Immunohistochemical staining to the latent nuclear antigen 1 of human herpesvirus 8 (HHV-8) confirms the KS diagnosis.5,6 Our patient's presentation as a solitary acral lesion was atypical for KS.  

Light microscopy of our patient's biopsy demonstrated a large tumor on the acral surface of the right hand. Dermal collections of basophilic spindled cells clustered with small slitlike vascular spaces with abundant erythrocyte extravasation and numerous large ectatic vessels at the periphery were seen (Figure, A). At higher magnification, interlaced bundles of spindle cells with slitlike vessels with scattered lymphocytes and plasma cells were seen (Figure, B). An immunohistochemical stain for HHV-8 was positive and largely confined to spindle cells (Figure, C). These findings confirmed KS and met AIDS-defining criteria. Awareness of these histopathologic features is key in differentiating KS from other conditions in the differential diagnosis.  

Kaposi sarcoma. A, Dermal collection of basophilic spindled cells clustered with small slitlike vascular spaces with abundant erythrocyte extravasation and numerous large ectatic vessels at the periphery (H&E, original magnification ×40). B, Interlaced bundles of spindle cells with slitlike vessels with scattered lymphocytes and plasma cells (H&E, original magnification ×400). C, Immunohistochemical staining showed human herpesvirus 8 positivity largely confined to spindle cells (original magnification ×20).

The patient's history of late latent syphilis coinfected with HIV and persistently elevated rapid plasma reagin that was recalcitrant to therapy placed an atypical nodular presentation within reason for the differential diagnosis. Deviations from the typical papulosquamous presentation with acral involvement in an immunocompromised patient mandates a consideration for syphilis with an atypical presentation. Atypical presentations include nodular, annular, pustular, lues maligna, frambesiform, corymbose, and photosensitive distributions.7,8 Notably, coinfection with HIV modifies the clinical presentation, serology, and efficacy of treatment.7-10 Atypical presentations are more common in coinfected HIV-positive patients, mandating a high degree of suspicion. Nodular secondary syphilis and the noduloulcerative form (lues maligna) often spare the palmar and plantar surfaces, and patients often have constitutional symptoms accompanying the cutaneous eruptions. In questionable cases, a biopsy lends clarification. Light microscopy on hematoxylin and eosin (H&E) staining may display acanthosis, superficial and deep perivascular swelling, plasma, histiocyte infiltrates, dermoepidermal junction changes, mixed patterns, epidermal hyperplasia, and dermal vascular thickening.7-9,11 Spirochetes may be observed on Warthin-Starry stain; however, artifact obscuration from melanin granules and reticular fibers or paucity of organisms can make identification difficult. Immunohistochemical staining may prove useful when H&E stains are atypical or have a paucity of organisms or plasma cells or when silver stains have artifactual obscuration.9 Our patient's solitary palmar lesion without constitutional symptoms made an atypical nodular secondary syphilis presentation less likely. Ultimately, the histopathologic findings were consistent with KS.  

Bacillary angiomatosis (BA) is caused by Bartonella species and results in vascular proliferation with cutaneous manifestation. It frequently is observed in patients with HIV or other immunosuppressive conditions as well as patients with exposure to mammals or their vectors. Protean cutaneous manifestations and distributions of BA exist. The number of lesions can be singular to thousands. Solitary superficial pyogenic granuloma-like lesions can be clinically indistinguishable from both KS and pyogenic granuloma (PG). Superficial lesions often begin as red, violaceous, or flesh-colored papules that hemorrhage easily with trauma. The morphology of the papule can progress to be exophytic with dome-shaped or ulcerative surface features and is rubbery on palpation.12 Biopsy is required to differentiate BA from KS. Bacillary angiomatosis on light microscopy with H&E shows protuberant, lobulated, round vessels with plump endothelial cells with or without necrosis. A neutrophil infiltrate in close proximity to bacilli may be noted. Warthin-Starry stain demonstrates numerous bacilli juxtaposed to these endothelial cells. The lack of immunohistochemical staining for HHV-8 also differentiates BA from KS.12,13  

Pyogenic granuloma is resultant from proliferation of endothelial cells with a lobular architecture. Pyogenic granulomas are benign, rapidly progressive, acquired lesions presenting in the skin and mucous membranes. Pyogenic granuloma often presents as a single painless papule or nodule with a glistening red-violaceous color that occasionally appears with a perilesional collarette. The lesions are friable and easily hemorrhage. Pyogenic granuloma has been associated with local skin trauma and estrogen hormones. Histopathologic examination of PG assists with differentiation from other nodular lesions. Light microscopy with standard H&E staining demonstrates a network of capillaries arranged into a lobule surrounded by a fibrous matrix. Endothelial cells appear round and protrude into the vascular lamina. Mitotic activity is increased. Lack of findings on Warthin-Starry stain assists with differentiating PG from BA, while the microscopy architecture and immunohistochemical staining differentiates PG from KS.6,13,14 

Squamous cell carcinoma (SCC) is the primary malignant cancer of the hand. The dorsal aspect of the hand is the most common location; SCC less commonly is located on the palmar surface, fingers, nail bed, or intertriginous areas.15-17 Chakrabarti et al16 found that these lesions were invasive SCC when located on the palmar surface. Morphologically, SCC takes an exophytic papular, nodular, or scaly appearance with a red to flesh-colored appearance and poor demarcation of the borders. Progression to large ulcerated or secondarily infected lesions also can occur. The inflammatory reaction may cause tenderness to palpation and hemorrhage with trauma. Histopathologic examination of invasive SCC reveals atypical keratinocytes violating the basement membrane and abundant cytoplasm. Our patient's clinical presentation placed invasive SCC low on the differential diagnosis, and the histopathologic and immunohistochemical results eliminated SCC as the diagnosis. 

The Diagnosis: Nodular Kaposi Sarcoma 

Epidemic Kaposi sarcoma (KS) primarily affects patients with human immunodeficiency virus (HIV) infection. Kaposi sarcoma can appear as brown, red, or blue-black macules, plaques, patches, nodules, or tumors, and it often is observed as multifocal cutaneous lesions located on the head, neck, and upper aspects of the trunk in a fulminant manner. Kaposi sarcoma portends a poor prognosis and is an AIDS-defining malignancy.1-3 Importantly, antiretroviral therapy does not preclude its consideration in those without AIDS-defining CD4 cell counts and undetectable HIV viremia presenting with cutaneous manifestations.2,3 A retrospective review by Daly et al4 reported KS lesions in patients with CD4 lymphocyte counts greater than 300 cells/µL, most of whom were antiretroviral therapy-naïve patients. Also, those with higher CD4 counts tended to have a solitary KS lesion at presentation, while those with CD4 counts less than 300 cells/µL tended to present with multiple foci.4 Epidemic KS lesions are clinically indistinguishable from other common cutaneous conditions in the differential diagnosis of KS, necessitating biopsy for histopathologic examination. Light microscopy findings help to delineate the diagnosis of KS. Immunohistochemical staining to the latent nuclear antigen 1 of human herpesvirus 8 (HHV-8) confirms the KS diagnosis.5,6 Our patient's presentation as a solitary acral lesion was atypical for KS.  

Light microscopy of our patient's biopsy demonstrated a large tumor on the acral surface of the right hand. Dermal collections of basophilic spindled cells clustered with small slitlike vascular spaces with abundant erythrocyte extravasation and numerous large ectatic vessels at the periphery were seen (Figure, A). At higher magnification, interlaced bundles of spindle cells with slitlike vessels with scattered lymphocytes and plasma cells were seen (Figure, B). An immunohistochemical stain for HHV-8 was positive and largely confined to spindle cells (Figure, C). These findings confirmed KS and met AIDS-defining criteria. Awareness of these histopathologic features is key in differentiating KS from other conditions in the differential diagnosis.  

Kaposi sarcoma. A, Dermal collection of basophilic spindled cells clustered with small slitlike vascular spaces with abundant erythrocyte extravasation and numerous large ectatic vessels at the periphery (H&E, original magnification ×40). B, Interlaced bundles of spindle cells with slitlike vessels with scattered lymphocytes and plasma cells (H&E, original magnification ×400). C, Immunohistochemical staining showed human herpesvirus 8 positivity largely confined to spindle cells (original magnification ×20).

The patient's history of late latent syphilis coinfected with HIV and persistently elevated rapid plasma reagin that was recalcitrant to therapy placed an atypical nodular presentation within reason for the differential diagnosis. Deviations from the typical papulosquamous presentation with acral involvement in an immunocompromised patient mandates a consideration for syphilis with an atypical presentation. Atypical presentations include nodular, annular, pustular, lues maligna, frambesiform, corymbose, and photosensitive distributions.7,8 Notably, coinfection with HIV modifies the clinical presentation, serology, and efficacy of treatment.7-10 Atypical presentations are more common in coinfected HIV-positive patients, mandating a high degree of suspicion. Nodular secondary syphilis and the noduloulcerative form (lues maligna) often spare the palmar and plantar surfaces, and patients often have constitutional symptoms accompanying the cutaneous eruptions. In questionable cases, a biopsy lends clarification. Light microscopy on hematoxylin and eosin (H&E) staining may display acanthosis, superficial and deep perivascular swelling, plasma, histiocyte infiltrates, dermoepidermal junction changes, mixed patterns, epidermal hyperplasia, and dermal vascular thickening.7-9,11 Spirochetes may be observed on Warthin-Starry stain; however, artifact obscuration from melanin granules and reticular fibers or paucity of organisms can make identification difficult. Immunohistochemical staining may prove useful when H&E stains are atypical or have a paucity of organisms or plasma cells or when silver stains have artifactual obscuration.9 Our patient's solitary palmar lesion without constitutional symptoms made an atypical nodular secondary syphilis presentation less likely. Ultimately, the histopathologic findings were consistent with KS.  

Bacillary angiomatosis (BA) is caused by Bartonella species and results in vascular proliferation with cutaneous manifestation. It frequently is observed in patients with HIV or other immunosuppressive conditions as well as patients with exposure to mammals or their vectors. Protean cutaneous manifestations and distributions of BA exist. The number of lesions can be singular to thousands. Solitary superficial pyogenic granuloma-like lesions can be clinically indistinguishable from both KS and pyogenic granuloma (PG). Superficial lesions often begin as red, violaceous, or flesh-colored papules that hemorrhage easily with trauma. The morphology of the papule can progress to be exophytic with dome-shaped or ulcerative surface features and is rubbery on palpation.12 Biopsy is required to differentiate BA from KS. Bacillary angiomatosis on light microscopy with H&E shows protuberant, lobulated, round vessels with plump endothelial cells with or without necrosis. A neutrophil infiltrate in close proximity to bacilli may be noted. Warthin-Starry stain demonstrates numerous bacilli juxtaposed to these endothelial cells. The lack of immunohistochemical staining for HHV-8 also differentiates BA from KS.12,13  

Pyogenic granuloma is resultant from proliferation of endothelial cells with a lobular architecture. Pyogenic granulomas are benign, rapidly progressive, acquired lesions presenting in the skin and mucous membranes. Pyogenic granuloma often presents as a single painless papule or nodule with a glistening red-violaceous color that occasionally appears with a perilesional collarette. The lesions are friable and easily hemorrhage. Pyogenic granuloma has been associated with local skin trauma and estrogen hormones. Histopathologic examination of PG assists with differentiation from other nodular lesions. Light microscopy with standard H&E staining demonstrates a network of capillaries arranged into a lobule surrounded by a fibrous matrix. Endothelial cells appear round and protrude into the vascular lamina. Mitotic activity is increased. Lack of findings on Warthin-Starry stain assists with differentiating PG from BA, while the microscopy architecture and immunohistochemical staining differentiates PG from KS.6,13,14 

Squamous cell carcinoma (SCC) is the primary malignant cancer of the hand. The dorsal aspect of the hand is the most common location; SCC less commonly is located on the palmar surface, fingers, nail bed, or intertriginous areas.15-17 Chakrabarti et al16 found that these lesions were invasive SCC when located on the palmar surface. Morphologically, SCC takes an exophytic papular, nodular, or scaly appearance with a red to flesh-colored appearance and poor demarcation of the borders. Progression to large ulcerated or secondarily infected lesions also can occur. The inflammatory reaction may cause tenderness to palpation and hemorrhage with trauma. Histopathologic examination of invasive SCC reveals atypical keratinocytes violating the basement membrane and abundant cytoplasm. Our patient's clinical presentation placed invasive SCC low on the differential diagnosis, and the histopathologic and immunohistochemical results eliminated SCC as the diagnosis. 

References
  1. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000;342:1027-1038.  
  2. Pipette WW. The incidence of second malignancies in subsets of Kaposi's sarcoma. J Am Acad Dermatol. 1987;16:855-861. 
  3. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS. 2017;12:6-11.  
  4. Daly ML, Fogo A, McDonald C, et al. Kaposi sarcoma: no longer an AIDS-defining illness? a retrospective study of Kaposi sarcoma cases with CD4 counts above 300/mm³ at presentation. Clin Exp Dermatol. 2014;39:7-12. 
  5. Broccolo F, Tassan Din C, Viganò MG, et al. HHV-8 DNA replication correlates with the clinical status in AIDS-related Kaposi's sarcoma. J Clin Virol. 2016;78:47-52. 
  6. Pereira PF, Cuzzi T, Galhardo MC. Immunohistochemical detection of the latent nuclear antigen-1 of the human herpesvirus type 8 to differentiate cutaneous epidemic Kaposi sarcoma and its histological simulators. An Bras Dermatol. 2013;88:243-246. 
  7. Gevorgyan O, Owen BD, Balavenkataraman A, et al. A nodular-ulcerative form of secondary syphilis in AIDS. Proc (Bayl Univ Med Cent). 2017;30:80-82. 
  8. Balagula Y, Mattei PL, Wisco OJ, et al. The great imitator revisited: the spectrum of atypical cutaneous manifestations of secondary syphilis. Int J Dermatol. 2014;53:1434-1441. 
  9. Hoang MP, High WA, Molberg KH. Secondary syphilis: a histologic and immunohistochemical evaluation. J Cutan Pathol. 2004;31:595-599. 
  10. Yayli S, della Torre R, Hegyi I, et al. Late secondary syphilis with nodular lesions mimicking Kaposi sarcoma in a patient with human immunodeficiency virus. Int J Dermatol. 2014;53:E71-E73. 
  11. Jeerapaet P, Ackerman AB. Histologic patterns of secondary syphilis. Arch Dermatol. 1973;107:373-377. 
  12. Cockerell CJ, LeBoit PE. Bacillary angiomatosis: a newly characterized, pseudoneoplastic, infectious, cutaneous vascular disorder. J Am Acad Dermatol. 1990;22:501-512.  
  13. Forrestel AK, Naujokas A, Martin JN, et al. Bacillary angiomatosis masquerading as Kaposi's sarcoma in East Africa. J Int Assoc Provid AIDS Care. 2015;14:21-25. 
  14. Fortna RR, Junkins-Hopkins JM. A case of lobular capillary hemangioma (pyogenic granuloma), localized to the subcutaneous tissue, and a review of the literature. Am J Dermatopathol. 2007;29:408-411. 
  15. Marks R. Squamous cell carcinoma. Lancet. 1996;347:735-738.  
  16. Chakrabarti I, Watson JD, Dorrance H. Skin tumours of the hand. a 10-year review. J Hand Surg Br. 1993;18:484-486. 
  17. Sobanko JF, Dagum AB, Davis IC, et al. Soft tissue tumors of the hand. 2. malignant. Dermatol Surg. 2007;33:771-785. 
References
  1. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000;342:1027-1038.  
  2. Pipette WW. The incidence of second malignancies in subsets of Kaposi's sarcoma. J Am Acad Dermatol. 1987;16:855-861. 
  3. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS. 2017;12:6-11.  
  4. Daly ML, Fogo A, McDonald C, et al. Kaposi sarcoma: no longer an AIDS-defining illness? a retrospective study of Kaposi sarcoma cases with CD4 counts above 300/mm³ at presentation. Clin Exp Dermatol. 2014;39:7-12. 
  5. Broccolo F, Tassan Din C, Viganò MG, et al. HHV-8 DNA replication correlates with the clinical status in AIDS-related Kaposi's sarcoma. J Clin Virol. 2016;78:47-52. 
  6. Pereira PF, Cuzzi T, Galhardo MC. Immunohistochemical detection of the latent nuclear antigen-1 of the human herpesvirus type 8 to differentiate cutaneous epidemic Kaposi sarcoma and its histological simulators. An Bras Dermatol. 2013;88:243-246. 
  7. Gevorgyan O, Owen BD, Balavenkataraman A, et al. A nodular-ulcerative form of secondary syphilis in AIDS. Proc (Bayl Univ Med Cent). 2017;30:80-82. 
  8. Balagula Y, Mattei PL, Wisco OJ, et al. The great imitator revisited: the spectrum of atypical cutaneous manifestations of secondary syphilis. Int J Dermatol. 2014;53:1434-1441. 
  9. Hoang MP, High WA, Molberg KH. Secondary syphilis: a histologic and immunohistochemical evaluation. J Cutan Pathol. 2004;31:595-599. 
  10. Yayli S, della Torre R, Hegyi I, et al. Late secondary syphilis with nodular lesions mimicking Kaposi sarcoma in a patient with human immunodeficiency virus. Int J Dermatol. 2014;53:E71-E73. 
  11. Jeerapaet P, Ackerman AB. Histologic patterns of secondary syphilis. Arch Dermatol. 1973;107:373-377. 
  12. Cockerell CJ, LeBoit PE. Bacillary angiomatosis: a newly characterized, pseudoneoplastic, infectious, cutaneous vascular disorder. J Am Acad Dermatol. 1990;22:501-512.  
  13. Forrestel AK, Naujokas A, Martin JN, et al. Bacillary angiomatosis masquerading as Kaposi's sarcoma in East Africa. J Int Assoc Provid AIDS Care. 2015;14:21-25. 
  14. Fortna RR, Junkins-Hopkins JM. A case of lobular capillary hemangioma (pyogenic granuloma), localized to the subcutaneous tissue, and a review of the literature. Am J Dermatopathol. 2007;29:408-411. 
  15. Marks R. Squamous cell carcinoma. Lancet. 1996;347:735-738.  
  16. Chakrabarti I, Watson JD, Dorrance H. Skin tumours of the hand. a 10-year review. J Hand Surg Br. 1993;18:484-486. 
  17. Sobanko JF, Dagum AB, Davis IC, et al. Soft tissue tumors of the hand. 2. malignant. Dermatol Surg. 2007;33:771-785. 
Issue
Cutis - 104(2)
Issue
Cutis - 104(2)
Page Number
E4-E6
Page Number
E4-E6
Publications
Publications
Topics
Article Type
Display Headline
Well-Circumscribed Tumor on the Hand
Display Headline
Well-Circumscribed Tumor on the Hand
Sections
Questionnaire Body

A 52-year-old man presented to the dermatology clinic with a 2×3-cm, fungating, dome-shaped, ulcerative, moist, well-circumscribed tumor with peripheral maceration on the volar aspect of the right hand of 3 months’ duration. The tumor was malodorous, painful, and hemorrhaged easily with minimal trauma. The patient’s medical history was notable for human immunodeficiency virus and latent syphilis, with elevated rapid plasma reagin titers and a positive Treponema palladium antibody on chemiluminescent immunoassay, that was refractory to 3 treatments with penicillin. The patient was not on antiretroviral therapy. He had a CD4+ lymphocyte count of 980 cells/µL (reference range, 359–1519 cells/µL) and a viral load of 8560 copies/mL (reference range, <200 copies/mL). No other skin or systemic concerns were noted, and the patient denied any recent travel, exposure to animals, or constitutional symptoms. A deep shave biopsy of the lesion was performed.

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Wed, 08/14/2019 - 10:30
Un-Gate On Date
Wed, 08/14/2019 - 10:30
Use ProPublica
CFC Schedule Remove Status
Wed, 08/14/2019 - 10:30
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

Rubbery Nodule on the Face of an Infant

Article Type
Changed
Fri, 01/31/2020 - 11:15

The Diagnosis: Juvenile Xanthogranuloma

Juvenile xanthogranuloma (JXG) was first described in 1905 by Adamson1 as solitary or multiple plaquiform or nodular lesions that are yellow to yellowish brown. In 1954, Helwig and Hackney2 coined the term juvenile xanthogranuloma to define this histiocytic cutaneous granulomatous tumor.

Juvenile xanthogranuloma is a rare dermatologic disorder that may be present at birth and primarily affects infants and young children. The benign lesions generally occur in the first 4 years of life, with a median age of onset of 2 years.3 Lesions range in size from millimeters to several centimeters in diameter.4 The skin of the head and neck is the most commonly involved site in JXG. The most frequent noncutaneous site of JXG involvement is the eye, particularly the iris, accounting for 0.4% of cases.5,6 Extracutaneous sites such as the heart, liver, lungs, spleen, oral cavity, and brain also may be involved.4

Most children with JXG are asymptomatic. Skin lesions present as well-demarcated, rubbery, tan-orange papules or nodules. They usually are solitary, and multiple nodules can increase the risk for extracutaneous involvement.4 A case series of patients with neurofibromatosis type 1 showed 14 of 77 (18%) patients examined in the first year of life presented with JXG or other non–Langerhans cell histiocytosis.7 The adult form of cutaneous xanthogranuloma often presents with severe bronchial asthma.8

Histopathologic examination of a biopsy of the lesion typically demonstrates well-circumscribed nodules with dense infiltrates of polyhedral histiocytes with vaculoles.3-7 In 85% of cases, Touton giant cells are present.4,9 A prominent vascular network often is present, which was observed in our patient’s biopsy (Figure 1). Immunohistochemistry typically is positive for CD14, CD68, CD163, fascin, and factor XIIIa.4,10 Classically, the cells are negative for S-100 and CD1a, which differentiates these lesions from Langerhans cell histiocytosis.4-7,10 Our patient demonstrated scattered S-100–positive cells representing background dendritic cells and macrophages (Figure 2). The remainder of the clinical, morphologic, and immunophenotypic findings were consistent with non–Langerhans cell histiocytosis, specifically JXG.

Biopsy should be performed in all cases, and basic laboratory test results such as a complete blood cell count and basic metabolic panel also are appropriate. Routine referral of all patients with cutaneous JXG for ophthalmologic evaluation is not recommended.11 Most patients with ocular involvement present with acute ocular concerns; asymptomatic eye involvement is rare. It is reasonable to consider referral to ophthalmology for patients younger than 2 years who present with multiple lesions, as they may have a higher risk for ocular involvement.11

Juvenile xanthogranuloma usually is a benign disorder with management involving observation, as the lesions typically involute spontaneously.3-7,9,10,12 Systemic or intralesional corticosteroids may be used for treatment in lesions that do not resolve. Ocular JXG refractory to steroid treatment has been managed in several cases with intravitreal bevacizumab.13 Additionally, surgical excision can be considered if malignancy is suspected, the lesion does not resolve with observation or steroid treatment, or the lesion is located near vital structures.4-7,9-13

Spitz nevus presents as a single dome-shaped papule, but histology shows a symmetrical proliferation of spindle and epithelioid cells. Trachoma can present in and around the eye as a follicular hypertrophy but most commonly is seen in the conjunctiva. Dermoid cysts present as solitary subcutaneous cystic lesions; histology demonstrates a lining of keratinizing squamous epithelium with the presence of pilosebaceous structures. Dermatofibroma appears as a tan to reddish-brown papule in an area of prior minor trauma; pathology demonstrates an acanthotic epidermis with an underlying zone of normal papillary dermis and unencapsulated lesions with spindle cells overlapping in fascicles and whorls at the periphery.

References

1. Adamson HG. Society intelligence: the Dermatological Society of
London. Br J Dermatol. 1905;17:222-223.

2. Helwig E, Hackney VC. Juvenile xanthogranuloma (nevoxanthoendothelioma).
Am J Pathol. 1954;30:625-626.

3. Farrugia EJ, Stephen AP, Raza SA. Juvenile xanthogranuloma of
temporal bone—a case report. J Laryngol Otol. 1997;111:63-65.

4. Cypel TK, Zuker RM. Juvenile xanthogranuloma: case report and review
of the literature. Can J Plast Surg. 2008;16:175-177.

5. Chang MW, Frieden IJ, Good W. The risk of intraocular juvenile
xanthogranuloma: survey of current practices and assessment of risk.
J Am Acad Dermatol. 1996;34:445-449.

6. Zimmerman LE. Ocular lesions of juvenile xanthogranuloma.
nevoxanthoendothelioma. Am J Ophthalmol. 1965;60:1011-1035.

7. Cambiaghi S, Restano L, Caputo R. Juvenile xanthogranuloma associated
with neurofibromatosis 1: 14 patients without evidence of hematologic
malignancies. Pediatr Dermatol. 2004;21:97-101.

8. Stover DG, Alapati S, Regueira O, et al. Treatment of juvenile xanthogranuloma.
Pediatr Blood Cancer. 2008;51:130-133.

9. Dehner LP. Juvenile xanthogranulomas in the first two decades of life. a
clinicopathologic study of 174 cases with cutaneous and extracutaneous
manifestations. Am J Surg Pathol. 2003;27:579-593.

10. Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-
Langerhans cell histiocytoses. Pediatr Blood Cancer. 2005;45:256-264.

11. Chang MW, Frieden IJ, Good W. The risk of intraocular juvenile
xanthogranuloma: survey of current practices and assessment of risk.
J Am Acad Dermatol. 1996;34:445.

12. Eggli KD, Caro P, Quioque T, et al. Juvenile xanthogranuloma: non-X
histiocytosis with systemic involvement. Pediatr Radiol. 1992;22:374-376.

13. Ashkenazy N, Henry CR, Abbey AM, et al. Successful treatment of juvenile
xanthogranuloma using bevacizumab. J AAPOS. 2014;18:295-297.

Article PDF
Author and Disclosure Information

From the University of Arkansas for Medical Sciences, Little Rock. Drs. Chancellor and Pemberton are from the Harvey and Bernice Jones Eye Institute, and Dr. Gonzalez-Krellwitz is from the Department of Pathology.

The authors report no conflict of interest.

Issue
Cutis - 104(2)
Publications
Topics
Page Number
92, 97-98
Sections
Author and Disclosure Information

From the University of Arkansas for Medical Sciences, Little Rock. Drs. Chancellor and Pemberton are from the Harvey and Bernice Jones Eye Institute, and Dr. Gonzalez-Krellwitz is from the Department of Pathology.

The authors report no conflict of interest.

Author and Disclosure Information

From the University of Arkansas for Medical Sciences, Little Rock. Drs. Chancellor and Pemberton are from the Harvey and Bernice Jones Eye Institute, and Dr. Gonzalez-Krellwitz is from the Department of Pathology.

The authors report no conflict of interest.

Article PDF
Article PDF

The Diagnosis: Juvenile Xanthogranuloma

Juvenile xanthogranuloma (JXG) was first described in 1905 by Adamson1 as solitary or multiple plaquiform or nodular lesions that are yellow to yellowish brown. In 1954, Helwig and Hackney2 coined the term juvenile xanthogranuloma to define this histiocytic cutaneous granulomatous tumor.

Juvenile xanthogranuloma is a rare dermatologic disorder that may be present at birth and primarily affects infants and young children. The benign lesions generally occur in the first 4 years of life, with a median age of onset of 2 years.3 Lesions range in size from millimeters to several centimeters in diameter.4 The skin of the head and neck is the most commonly involved site in JXG. The most frequent noncutaneous site of JXG involvement is the eye, particularly the iris, accounting for 0.4% of cases.5,6 Extracutaneous sites such as the heart, liver, lungs, spleen, oral cavity, and brain also may be involved.4

Most children with JXG are asymptomatic. Skin lesions present as well-demarcated, rubbery, tan-orange papules or nodules. They usually are solitary, and multiple nodules can increase the risk for extracutaneous involvement.4 A case series of patients with neurofibromatosis type 1 showed 14 of 77 (18%) patients examined in the first year of life presented with JXG or other non–Langerhans cell histiocytosis.7 The adult form of cutaneous xanthogranuloma often presents with severe bronchial asthma.8

Histopathologic examination of a biopsy of the lesion typically demonstrates well-circumscribed nodules with dense infiltrates of polyhedral histiocytes with vaculoles.3-7 In 85% of cases, Touton giant cells are present.4,9 A prominent vascular network often is present, which was observed in our patient’s biopsy (Figure 1). Immunohistochemistry typically is positive for CD14, CD68, CD163, fascin, and factor XIIIa.4,10 Classically, the cells are negative for S-100 and CD1a, which differentiates these lesions from Langerhans cell histiocytosis.4-7,10 Our patient demonstrated scattered S-100–positive cells representing background dendritic cells and macrophages (Figure 2). The remainder of the clinical, morphologic, and immunophenotypic findings were consistent with non–Langerhans cell histiocytosis, specifically JXG.

Biopsy should be performed in all cases, and basic laboratory test results such as a complete blood cell count and basic metabolic panel also are appropriate. Routine referral of all patients with cutaneous JXG for ophthalmologic evaluation is not recommended.11 Most patients with ocular involvement present with acute ocular concerns; asymptomatic eye involvement is rare. It is reasonable to consider referral to ophthalmology for patients younger than 2 years who present with multiple lesions, as they may have a higher risk for ocular involvement.11

Juvenile xanthogranuloma usually is a benign disorder with management involving observation, as the lesions typically involute spontaneously.3-7,9,10,12 Systemic or intralesional corticosteroids may be used for treatment in lesions that do not resolve. Ocular JXG refractory to steroid treatment has been managed in several cases with intravitreal bevacizumab.13 Additionally, surgical excision can be considered if malignancy is suspected, the lesion does not resolve with observation or steroid treatment, or the lesion is located near vital structures.4-7,9-13

Spitz nevus presents as a single dome-shaped papule, but histology shows a symmetrical proliferation of spindle and epithelioid cells. Trachoma can present in and around the eye as a follicular hypertrophy but most commonly is seen in the conjunctiva. Dermoid cysts present as solitary subcutaneous cystic lesions; histology demonstrates a lining of keratinizing squamous epithelium with the presence of pilosebaceous structures. Dermatofibroma appears as a tan to reddish-brown papule in an area of prior minor trauma; pathology demonstrates an acanthotic epidermis with an underlying zone of normal papillary dermis and unencapsulated lesions with spindle cells overlapping in fascicles and whorls at the periphery.

The Diagnosis: Juvenile Xanthogranuloma

Juvenile xanthogranuloma (JXG) was first described in 1905 by Adamson1 as solitary or multiple plaquiform or nodular lesions that are yellow to yellowish brown. In 1954, Helwig and Hackney2 coined the term juvenile xanthogranuloma to define this histiocytic cutaneous granulomatous tumor.

Juvenile xanthogranuloma is a rare dermatologic disorder that may be present at birth and primarily affects infants and young children. The benign lesions generally occur in the first 4 years of life, with a median age of onset of 2 years.3 Lesions range in size from millimeters to several centimeters in diameter.4 The skin of the head and neck is the most commonly involved site in JXG. The most frequent noncutaneous site of JXG involvement is the eye, particularly the iris, accounting for 0.4% of cases.5,6 Extracutaneous sites such as the heart, liver, lungs, spleen, oral cavity, and brain also may be involved.4

Most children with JXG are asymptomatic. Skin lesions present as well-demarcated, rubbery, tan-orange papules or nodules. They usually are solitary, and multiple nodules can increase the risk for extracutaneous involvement.4 A case series of patients with neurofibromatosis type 1 showed 14 of 77 (18%) patients examined in the first year of life presented with JXG or other non–Langerhans cell histiocytosis.7 The adult form of cutaneous xanthogranuloma often presents with severe bronchial asthma.8

Histopathologic examination of a biopsy of the lesion typically demonstrates well-circumscribed nodules with dense infiltrates of polyhedral histiocytes with vaculoles.3-7 In 85% of cases, Touton giant cells are present.4,9 A prominent vascular network often is present, which was observed in our patient’s biopsy (Figure 1). Immunohistochemistry typically is positive for CD14, CD68, CD163, fascin, and factor XIIIa.4,10 Classically, the cells are negative for S-100 and CD1a, which differentiates these lesions from Langerhans cell histiocytosis.4-7,10 Our patient demonstrated scattered S-100–positive cells representing background dendritic cells and macrophages (Figure 2). The remainder of the clinical, morphologic, and immunophenotypic findings were consistent with non–Langerhans cell histiocytosis, specifically JXG.

Biopsy should be performed in all cases, and basic laboratory test results such as a complete blood cell count and basic metabolic panel also are appropriate. Routine referral of all patients with cutaneous JXG for ophthalmologic evaluation is not recommended.11 Most patients with ocular involvement present with acute ocular concerns; asymptomatic eye involvement is rare. It is reasonable to consider referral to ophthalmology for patients younger than 2 years who present with multiple lesions, as they may have a higher risk for ocular involvement.11

Juvenile xanthogranuloma usually is a benign disorder with management involving observation, as the lesions typically involute spontaneously.3-7,9,10,12 Systemic or intralesional corticosteroids may be used for treatment in lesions that do not resolve. Ocular JXG refractory to steroid treatment has been managed in several cases with intravitreal bevacizumab.13 Additionally, surgical excision can be considered if malignancy is suspected, the lesion does not resolve with observation or steroid treatment, or the lesion is located near vital structures.4-7,9-13

Spitz nevus presents as a single dome-shaped papule, but histology shows a symmetrical proliferation of spindle and epithelioid cells. Trachoma can present in and around the eye as a follicular hypertrophy but most commonly is seen in the conjunctiva. Dermoid cysts present as solitary subcutaneous cystic lesions; histology demonstrates a lining of keratinizing squamous epithelium with the presence of pilosebaceous structures. Dermatofibroma appears as a tan to reddish-brown papule in an area of prior minor trauma; pathology demonstrates an acanthotic epidermis with an underlying zone of normal papillary dermis and unencapsulated lesions with spindle cells overlapping in fascicles and whorls at the periphery.

References

1. Adamson HG. Society intelligence: the Dermatological Society of
London. Br J Dermatol. 1905;17:222-223.

2. Helwig E, Hackney VC. Juvenile xanthogranuloma (nevoxanthoendothelioma).
Am J Pathol. 1954;30:625-626.

3. Farrugia EJ, Stephen AP, Raza SA. Juvenile xanthogranuloma of
temporal bone—a case report. J Laryngol Otol. 1997;111:63-65.

4. Cypel TK, Zuker RM. Juvenile xanthogranuloma: case report and review
of the literature. Can J Plast Surg. 2008;16:175-177.

5. Chang MW, Frieden IJ, Good W. The risk of intraocular juvenile
xanthogranuloma: survey of current practices and assessment of risk.
J Am Acad Dermatol. 1996;34:445-449.

6. Zimmerman LE. Ocular lesions of juvenile xanthogranuloma.
nevoxanthoendothelioma. Am J Ophthalmol. 1965;60:1011-1035.

7. Cambiaghi S, Restano L, Caputo R. Juvenile xanthogranuloma associated
with neurofibromatosis 1: 14 patients without evidence of hematologic
malignancies. Pediatr Dermatol. 2004;21:97-101.

8. Stover DG, Alapati S, Regueira O, et al. Treatment of juvenile xanthogranuloma.
Pediatr Blood Cancer. 2008;51:130-133.

9. Dehner LP. Juvenile xanthogranulomas in the first two decades of life. a
clinicopathologic study of 174 cases with cutaneous and extracutaneous
manifestations. Am J Surg Pathol. 2003;27:579-593.

10. Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-
Langerhans cell histiocytoses. Pediatr Blood Cancer. 2005;45:256-264.

11. Chang MW, Frieden IJ, Good W. The risk of intraocular juvenile
xanthogranuloma: survey of current practices and assessment of risk.
J Am Acad Dermatol. 1996;34:445.

12. Eggli KD, Caro P, Quioque T, et al. Juvenile xanthogranuloma: non-X
histiocytosis with systemic involvement. Pediatr Radiol. 1992;22:374-376.

13. Ashkenazy N, Henry CR, Abbey AM, et al. Successful treatment of juvenile
xanthogranuloma using bevacizumab. J AAPOS. 2014;18:295-297.

References

1. Adamson HG. Society intelligence: the Dermatological Society of
London. Br J Dermatol. 1905;17:222-223.

2. Helwig E, Hackney VC. Juvenile xanthogranuloma (nevoxanthoendothelioma).
Am J Pathol. 1954;30:625-626.

3. Farrugia EJ, Stephen AP, Raza SA. Juvenile xanthogranuloma of
temporal bone—a case report. J Laryngol Otol. 1997;111:63-65.

4. Cypel TK, Zuker RM. Juvenile xanthogranuloma: case report and review
of the literature. Can J Plast Surg. 2008;16:175-177.

5. Chang MW, Frieden IJ, Good W. The risk of intraocular juvenile
xanthogranuloma: survey of current practices and assessment of risk.
J Am Acad Dermatol. 1996;34:445-449.

6. Zimmerman LE. Ocular lesions of juvenile xanthogranuloma.
nevoxanthoendothelioma. Am J Ophthalmol. 1965;60:1011-1035.

7. Cambiaghi S, Restano L, Caputo R. Juvenile xanthogranuloma associated
with neurofibromatosis 1: 14 patients without evidence of hematologic
malignancies. Pediatr Dermatol. 2004;21:97-101.

8. Stover DG, Alapati S, Regueira O, et al. Treatment of juvenile xanthogranuloma.
Pediatr Blood Cancer. 2008;51:130-133.

9. Dehner LP. Juvenile xanthogranulomas in the first two decades of life. a
clinicopathologic study of 174 cases with cutaneous and extracutaneous
manifestations. Am J Surg Pathol. 2003;27:579-593.

10. Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-
Langerhans cell histiocytoses. Pediatr Blood Cancer. 2005;45:256-264.

11. Chang MW, Frieden IJ, Good W. The risk of intraocular juvenile
xanthogranuloma: survey of current practices and assessment of risk.
J Am Acad Dermatol. 1996;34:445.

12. Eggli KD, Caro P, Quioque T, et al. Juvenile xanthogranuloma: non-X
histiocytosis with systemic involvement. Pediatr Radiol. 1992;22:374-376.

13. Ashkenazy N, Henry CR, Abbey AM, et al. Successful treatment of juvenile
xanthogranuloma using bevacizumab. J AAPOS. 2014;18:295-297.

Issue
Cutis - 104(2)
Issue
Cutis - 104(2)
Page Number
92, 97-98
Page Number
92, 97-98
Publications
Publications
Topics
Article Type
Sections
Questionnaire Body

A 10-month-old girl presented with a facial nodule of 7 months’ duration that started as a small lesion. On physical examination, a single 10×10-mm, nontender, well-circumscribed, firm, freely mobile nodule was observed in the left infraorbital area. The patient was born full term at 37 weeks’ gestation via spontaneous vaginal delivery and had no other notable findings on physical examination. Excision was performed by an oculoplastic surgeon. Pathology revealed a relatively well-circumscribed, diffuse, dermal infiltrate of cells arranged in short fascicles and a storiform pattern. The cells had abundant clear to amphophilic cytoplasm, ovoid to reniform nuclei with vesicular chromatin and focal grooves, and diffuse CD68+ immunoreactivity, as well as scattered S-100–positive cells. The patient did well with the excision and no new lesions have developed.

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 08/06/2019 - 13:45
Un-Gate On Date
Tue, 08/06/2019 - 13:45
Use ProPublica
CFC Schedule Remove Status
Tue, 08/06/2019 - 13:45
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

Rapidly Growing Retroauricular Tumor

Article Type
Changed
Tue, 08/06/2019 - 13:30
Display Headline
Rapidly Growing Retroauricular Tumor

The Diagnosis: Milia En Plaque 

Biopsy results revealed a normal epidermis; the dermis showed multiple small cystic structures lined by a stratified squamous epithelium containing eosinophilic keratin surrounded by a mononuclear cell infiltrate and some melanophages (Figure).  

Histopathology revealed a normal epidermis; the dermis showed multiple small cystic structures lined by a stratified squamous epithelium containing eosinophilic keratin surrounded by a mononuclear cell infiltrate and some melanophages (H&E, original magnification ×40).

Milia en plaque was first described in 1903 by Balzer and Fouquet.1 In 1978, Hubler et al2 presented 2 cases with an asymptomatic, erythematous, and edematous plaque and white milialike lesions. On histopathology, they showed multiple cystic structures characterized by central laminated keratin and an intense polymorphic inflammatory reaction surrounding the cyst and epidermal appendages. Both patients were treated with topical tretinoin with complete response at 3 months. The authors suggested the term milia en plaque to describe this clinical entity.

Milia en plaque is described as an infrequent condition that more often presents on the head, neck, and trunk, as well as the periocular, periauricular, and perinasal areas. It has been reported to occur at any age3 but appears more frequently in middle-aged adults and females. A congenital case also has been reported.4 It has been associated with pseudoxanthoma elasticum, lichen planus, trauma, kidney transplant, and cyclosporine use, but it also can present in healthy individuals,3 as in our patient. No clear cause has been identified. 

Pathology is characteristic, with multiple cysts filled with keratin and surrounded by 2 or 3 layers of epithelial cells, associated with a mononuclear, nonlichenoid, mononuclear infiltrate.5 Structures similar to follicular infundibular tumors have been described, suggesting a common origin of follicular lesions as milia en plaque.6  

Treatment includes surgical excision, cryosurgery, dermabrasion, electrodesiccation, trichloroacetic acid, photodynamic therapy, CO2 and erbium lasers, topical retinoids, minocycline, and etretinate.7 We performed a complete surgical excision in our patient.  

In acneform reactions, erythematous papules and pustules can be found on the cheeks and forehead. Nevus comedonicus appears during childhood and presents with multiple open comedones. Postinflammatory milia is present in chronic inflammatory pathologies such as porphyria cutanea tarda. Histopathologic findings in adnexal tumors show a benign proliferation of any cellular type of a cutaneous annex. 

Milia en plaque is an unusual but benign condition that is distinguished clinically by its characteristic presentation. 

References
  1. Balzer F, Fouquet C. Milium confluent retroauricularies bilateral. Bull Soc Fr Dermatol Syphiligr. 1903;14:361.  
  2. Hubler WR, Rudolph AH, Kelleher RM. Milia en plaque. Cutis. 1978;22:67-70. 
  3. Berk DR, Bayliss SJ. Milia: a review and classification. J Am Acad Dermatol. 2008;59:1050-1063. 
  4. Wang AR, Bercovitch L. Congenital milia en plaque. Pediatr Dermatol. 2016;33:258-259. 
  5. Muñoz-Martínez R, Santamarina-Albertos A, Sanz-Muñoz C, et al. Milia en plaque. Actas Dermosifiliogr. 2013;104:638-640. 
  6. Terui H, Hashimoto A, Yamasaki K, et al. Milia en plaque as a distinct follicular hamartoma with cystic trichoepitheliomatous features. Am J Dermatopathol. 2016;38:212-217.  
  7. Tenna S, Filoni A, Pagliarello C, et al. Eyelid milia en plaque: a treatment challenge with a new CO2 fractional laser. Dermatol Ther. 2014;27:65-67.
Article PDF
Author and Disclosure Information

Dr. Ducommun is from the Dermatology Department, Universidad de Chile, Santiago. Drs. Herschman and Huber are from Clinical Hospital Universidad de Chile. Dr. Herschman is from the Dermatology Service, and Dr. Huber is from the Pathology Service.

The authors report no conflict of interest.

Correspondence: Carlos Palma Ducommun, MD, Santos Dumont 999, Independencia, Santiago, Chile (cafrapa@gmail.com)

Issue
Cutis - 104(1)
Publications
Topics
Page Number
E17-E18
Sections
Author and Disclosure Information

Dr. Ducommun is from the Dermatology Department, Universidad de Chile, Santiago. Drs. Herschman and Huber are from Clinical Hospital Universidad de Chile. Dr. Herschman is from the Dermatology Service, and Dr. Huber is from the Pathology Service.

The authors report no conflict of interest.

Correspondence: Carlos Palma Ducommun, MD, Santos Dumont 999, Independencia, Santiago, Chile (cafrapa@gmail.com)

Author and Disclosure Information

Dr. Ducommun is from the Dermatology Department, Universidad de Chile, Santiago. Drs. Herschman and Huber are from Clinical Hospital Universidad de Chile. Dr. Herschman is from the Dermatology Service, and Dr. Huber is from the Pathology Service.

The authors report no conflict of interest.

Correspondence: Carlos Palma Ducommun, MD, Santos Dumont 999, Independencia, Santiago, Chile (cafrapa@gmail.com)

Article PDF
Article PDF
Related Articles

The Diagnosis: Milia En Plaque 

Biopsy results revealed a normal epidermis; the dermis showed multiple small cystic structures lined by a stratified squamous epithelium containing eosinophilic keratin surrounded by a mononuclear cell infiltrate and some melanophages (Figure).  

Histopathology revealed a normal epidermis; the dermis showed multiple small cystic structures lined by a stratified squamous epithelium containing eosinophilic keratin surrounded by a mononuclear cell infiltrate and some melanophages (H&E, original magnification ×40).

Milia en plaque was first described in 1903 by Balzer and Fouquet.1 In 1978, Hubler et al2 presented 2 cases with an asymptomatic, erythematous, and edematous plaque and white milialike lesions. On histopathology, they showed multiple cystic structures characterized by central laminated keratin and an intense polymorphic inflammatory reaction surrounding the cyst and epidermal appendages. Both patients were treated with topical tretinoin with complete response at 3 months. The authors suggested the term milia en plaque to describe this clinical entity.

Milia en plaque is described as an infrequent condition that more often presents on the head, neck, and trunk, as well as the periocular, periauricular, and perinasal areas. It has been reported to occur at any age3 but appears more frequently in middle-aged adults and females. A congenital case also has been reported.4 It has been associated with pseudoxanthoma elasticum, lichen planus, trauma, kidney transplant, and cyclosporine use, but it also can present in healthy individuals,3 as in our patient. No clear cause has been identified. 

Pathology is characteristic, with multiple cysts filled with keratin and surrounded by 2 or 3 layers of epithelial cells, associated with a mononuclear, nonlichenoid, mononuclear infiltrate.5 Structures similar to follicular infundibular tumors have been described, suggesting a common origin of follicular lesions as milia en plaque.6  

Treatment includes surgical excision, cryosurgery, dermabrasion, electrodesiccation, trichloroacetic acid, photodynamic therapy, CO2 and erbium lasers, topical retinoids, minocycline, and etretinate.7 We performed a complete surgical excision in our patient.  

In acneform reactions, erythematous papules and pustules can be found on the cheeks and forehead. Nevus comedonicus appears during childhood and presents with multiple open comedones. Postinflammatory milia is present in chronic inflammatory pathologies such as porphyria cutanea tarda. Histopathologic findings in adnexal tumors show a benign proliferation of any cellular type of a cutaneous annex. 

Milia en plaque is an unusual but benign condition that is distinguished clinically by its characteristic presentation. 

The Diagnosis: Milia En Plaque 

Biopsy results revealed a normal epidermis; the dermis showed multiple small cystic structures lined by a stratified squamous epithelium containing eosinophilic keratin surrounded by a mononuclear cell infiltrate and some melanophages (Figure).  

Histopathology revealed a normal epidermis; the dermis showed multiple small cystic structures lined by a stratified squamous epithelium containing eosinophilic keratin surrounded by a mononuclear cell infiltrate and some melanophages (H&E, original magnification ×40).

Milia en plaque was first described in 1903 by Balzer and Fouquet.1 In 1978, Hubler et al2 presented 2 cases with an asymptomatic, erythematous, and edematous plaque and white milialike lesions. On histopathology, they showed multiple cystic structures characterized by central laminated keratin and an intense polymorphic inflammatory reaction surrounding the cyst and epidermal appendages. Both patients were treated with topical tretinoin with complete response at 3 months. The authors suggested the term milia en plaque to describe this clinical entity.

Milia en plaque is described as an infrequent condition that more often presents on the head, neck, and trunk, as well as the periocular, periauricular, and perinasal areas. It has been reported to occur at any age3 but appears more frequently in middle-aged adults and females. A congenital case also has been reported.4 It has been associated with pseudoxanthoma elasticum, lichen planus, trauma, kidney transplant, and cyclosporine use, but it also can present in healthy individuals,3 as in our patient. No clear cause has been identified. 

Pathology is characteristic, with multiple cysts filled with keratin and surrounded by 2 or 3 layers of epithelial cells, associated with a mononuclear, nonlichenoid, mononuclear infiltrate.5 Structures similar to follicular infundibular tumors have been described, suggesting a common origin of follicular lesions as milia en plaque.6  

Treatment includes surgical excision, cryosurgery, dermabrasion, electrodesiccation, trichloroacetic acid, photodynamic therapy, CO2 and erbium lasers, topical retinoids, minocycline, and etretinate.7 We performed a complete surgical excision in our patient.  

In acneform reactions, erythematous papules and pustules can be found on the cheeks and forehead. Nevus comedonicus appears during childhood and presents with multiple open comedones. Postinflammatory milia is present in chronic inflammatory pathologies such as porphyria cutanea tarda. Histopathologic findings in adnexal tumors show a benign proliferation of any cellular type of a cutaneous annex. 

Milia en plaque is an unusual but benign condition that is distinguished clinically by its characteristic presentation. 

References
  1. Balzer F, Fouquet C. Milium confluent retroauricularies bilateral. Bull Soc Fr Dermatol Syphiligr. 1903;14:361.  
  2. Hubler WR, Rudolph AH, Kelleher RM. Milia en plaque. Cutis. 1978;22:67-70. 
  3. Berk DR, Bayliss SJ. Milia: a review and classification. J Am Acad Dermatol. 2008;59:1050-1063. 
  4. Wang AR, Bercovitch L. Congenital milia en plaque. Pediatr Dermatol. 2016;33:258-259. 
  5. Muñoz-Martínez R, Santamarina-Albertos A, Sanz-Muñoz C, et al. Milia en plaque. Actas Dermosifiliogr. 2013;104:638-640. 
  6. Terui H, Hashimoto A, Yamasaki K, et al. Milia en plaque as a distinct follicular hamartoma with cystic trichoepitheliomatous features. Am J Dermatopathol. 2016;38:212-217.  
  7. Tenna S, Filoni A, Pagliarello C, et al. Eyelid milia en plaque: a treatment challenge with a new CO2 fractional laser. Dermatol Ther. 2014;27:65-67.
References
  1. Balzer F, Fouquet C. Milium confluent retroauricularies bilateral. Bull Soc Fr Dermatol Syphiligr. 1903;14:361.  
  2. Hubler WR, Rudolph AH, Kelleher RM. Milia en plaque. Cutis. 1978;22:67-70. 
  3. Berk DR, Bayliss SJ. Milia: a review and classification. J Am Acad Dermatol. 2008;59:1050-1063. 
  4. Wang AR, Bercovitch L. Congenital milia en plaque. Pediatr Dermatol. 2016;33:258-259. 
  5. Muñoz-Martínez R, Santamarina-Albertos A, Sanz-Muñoz C, et al. Milia en plaque. Actas Dermosifiliogr. 2013;104:638-640. 
  6. Terui H, Hashimoto A, Yamasaki K, et al. Milia en plaque as a distinct follicular hamartoma with cystic trichoepitheliomatous features. Am J Dermatopathol. 2016;38:212-217.  
  7. Tenna S, Filoni A, Pagliarello C, et al. Eyelid milia en plaque: a treatment challenge with a new CO2 fractional laser. Dermatol Ther. 2014;27:65-67.
Issue
Cutis - 104(1)
Issue
Cutis - 104(1)
Page Number
E17-E18
Page Number
E17-E18
Publications
Publications
Topics
Article Type
Display Headline
Rapidly Growing Retroauricular Tumor
Display Headline
Rapidly Growing Retroauricular Tumor
Sections
Questionnaire Body

A 72-year-old man with a history of hypertension presented with a rapidly growing left retroauricular tumor of 3 months' duration. When manipulated, whitish material with a foul-smelling odor was expressed from the lesion. Physical examination showed an erythematous 3.2 ×1-cm tumor on the left posterior ear with multiple 1- to 2-mm white-yellow papules on its surface. A biopsy of the lesion was performed. 

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 07/30/2019 - 12:00
Un-Gate On Date
Tue, 07/30/2019 - 12:00
Use ProPublica
CFC Schedule Remove Status
Tue, 07/30/2019 - 12:00
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

Painless Purple Streaks on the Arms and Chest

Article Type
Changed
Tue, 07/23/2019 - 11:27
Display Headline
Painless Purple Streaks on the Arms and Chest

The Diagnosis: Factitial Purpura 

Factitial dermatologic disorders are characterized by skin findings triggered by deliberate manipulation of the skin with objects to create lesions and feign signs of a dermatologic condition to seek emotional and psychological benefit.1 The etiology of the lesions is unclear, and the patient's history of the injury is hollow.2 Most often, there is sudden onset of the lesions without any warning or symptoms. When giving the history, the patient may appear unemotional, does not report pain, and denies self-infliction.1  

In factitial purpura, the purple patches are clearly demarcated from uninvolved skin and have an unusual angular or geometric shape. The pattern typically takes the shape of the object used to create the purpura and lacks the features of recognizable dermatoses.2 In our patient and those with similar linear purpuric streaks, we use the term penny purpura to indicate that the lesions resulted from rubbing with a penny or other blunt object, similar to coining. The lesions occur in areas that are easily accessible and visible such as the arms, chest, or chin. It is suggested that the child unconsciously wants the lesions to be seen. Histologic findings in factitial purpura include disruption of collagen fiber bundles and extravasated red blood cells in the dermis.3 Unfortunately, evolving lesions may give nonspecific histologic findings; when the clinical lesions are typical, skin biopsy usually is unnecessary and may be misleading. Laboratory test results such as complete blood cell count, prothrombin time, and partial thromboplastin time usually are within reference range, as in our patient. 

When evaluating these patients, confrontation is not recommended. More than two-thirds of affected patients have a history of trauma such as sexual/physical abuse or neglect, and the lesions typically arise during times of stress.1,3 Thus, treatment includes nonaccusatory measures and referral for psychologic evaluation. The purpura will rapidly heal when covered with an occlusive dressing.2  

The differential diagnosis for penny purpura includes lesions that evolve from cupping and coining. Cupping is a type of complementary and alternative medicine that acts by correcting imbalances in the internal biofield and restoring the flow of qi, which determines the state of one's health and life span.4 Cupping is performed by placing a glass cup over a painful body part. A partial vacuum is created by flaming, mechanical withdrawal, or thermal cooling of the entrapped air under the cup. When the flame exhausts the supply of oxygen, the skin is sucked into the mouth of the glass, and the skin is bruised painlessly.4  

The differential also includes child maltreatment syndrome and other disorders that would potentiate bruising. Intravascular etiologies include idiopathic thrombocytopenic purpura, leukemia, coagulation disorders, and other causes of thrombocytopenia or platelet dysfunction.3 Extravascular etiologies include hereditary collagen vascular disease (eg, Ehlers-Danlos syndrome), malnutrition, and other disorders associated with a decrease in collagen and other tissues that support cutaneous vessels. Vascular etiologies include infectious (eg, Rocky Mountain spotted fever, meningococcemia) and noninfectious vasculitis (eg, Henoch-Schönlein purpura), leaky capillary syndrome, drug reactions, and other disorders associated with a loss of vascular integrity.3  

It is important to be able to differentiate self-inflicted lesions in a person who repeatedly acts as if he/she has a physical disorder from those that are created during the practices of cupping or any other cultural healing practice. Vascular disorders, malnutrition, and child abuse also should be excluded.3  

For our patient with factitial purpura, we gently encouraged the family to work with the child's pediatrician and a pediatric psychologist to deal with stress related to the recurrent rash and asked them to think of the rash as a result of an external cause; however, we were careful not to blame anyone for the rash.  

References
  1. Harth W, Taube KM, Gieler U. Facticious disorders in dermatology. J Dtsch Dermatol Ges. 2010;8:361-372; quiz 373.  
  2. Al Hawsawi K, Pope E. Pediatric psychocutaneous disorders: a review of primary psychiatric disorders with dermatologic manifestations. Am J Clin Dermatol. 2011;12:247-257.  
  3. Ring HC, Miller IM, Benfeldt E, et al. Artefactual skin lesions in children and adolescents: review of the literature and two cases of factitious purpura. Int J Dermatol. 2015;54:E27-E32. 
  4. Mehta P, Dhapte V. Cupping therapy: a prudent remedy for a plethora of medical ailments. J Tradit Complement Med. 2015;5:127-134. 
Article PDF
Author and Disclosure Information

Dr. Alexander was from the University of Maryland, Baltimore, and currently is from the Department of Dermatology, Duke University Medical Center, Durham, North Carolina. Dr. Cohen is from the Department of Dermatology, Division of Pediatric Dermatology, Johns Hopkins University School of Medicine, Baltimore.

The authors report no conflict of interest.

Correspondence: Bernard Cohen, MD, Johns Hopkins University School of Medicine, Division of Pediatric Dermatology, David M. Rubenstein Child Health Bldg, Ste 2107, 200 N Wolfe St, Baltimore, MD 21287 (bcohena@jhmi.edu)

Issue
Cutis - 104(1)
Publications
Topics
Page Number
E8-E9
Sections
Author and Disclosure Information

Dr. Alexander was from the University of Maryland, Baltimore, and currently is from the Department of Dermatology, Duke University Medical Center, Durham, North Carolina. Dr. Cohen is from the Department of Dermatology, Division of Pediatric Dermatology, Johns Hopkins University School of Medicine, Baltimore.

The authors report no conflict of interest.

Correspondence: Bernard Cohen, MD, Johns Hopkins University School of Medicine, Division of Pediatric Dermatology, David M. Rubenstein Child Health Bldg, Ste 2107, 200 N Wolfe St, Baltimore, MD 21287 (bcohena@jhmi.edu)

Author and Disclosure Information

Dr. Alexander was from the University of Maryland, Baltimore, and currently is from the Department of Dermatology, Duke University Medical Center, Durham, North Carolina. Dr. Cohen is from the Department of Dermatology, Division of Pediatric Dermatology, Johns Hopkins University School of Medicine, Baltimore.

The authors report no conflict of interest.

Correspondence: Bernard Cohen, MD, Johns Hopkins University School of Medicine, Division of Pediatric Dermatology, David M. Rubenstein Child Health Bldg, Ste 2107, 200 N Wolfe St, Baltimore, MD 21287 (bcohena@jhmi.edu)

Article PDF
Article PDF
Related Articles

The Diagnosis: Factitial Purpura 

Factitial dermatologic disorders are characterized by skin findings triggered by deliberate manipulation of the skin with objects to create lesions and feign signs of a dermatologic condition to seek emotional and psychological benefit.1 The etiology of the lesions is unclear, and the patient's history of the injury is hollow.2 Most often, there is sudden onset of the lesions without any warning or symptoms. When giving the history, the patient may appear unemotional, does not report pain, and denies self-infliction.1  

In factitial purpura, the purple patches are clearly demarcated from uninvolved skin and have an unusual angular or geometric shape. The pattern typically takes the shape of the object used to create the purpura and lacks the features of recognizable dermatoses.2 In our patient and those with similar linear purpuric streaks, we use the term penny purpura to indicate that the lesions resulted from rubbing with a penny or other blunt object, similar to coining. The lesions occur in areas that are easily accessible and visible such as the arms, chest, or chin. It is suggested that the child unconsciously wants the lesions to be seen. Histologic findings in factitial purpura include disruption of collagen fiber bundles and extravasated red blood cells in the dermis.3 Unfortunately, evolving lesions may give nonspecific histologic findings; when the clinical lesions are typical, skin biopsy usually is unnecessary and may be misleading. Laboratory test results such as complete blood cell count, prothrombin time, and partial thromboplastin time usually are within reference range, as in our patient. 

When evaluating these patients, confrontation is not recommended. More than two-thirds of affected patients have a history of trauma such as sexual/physical abuse or neglect, and the lesions typically arise during times of stress.1,3 Thus, treatment includes nonaccusatory measures and referral for psychologic evaluation. The purpura will rapidly heal when covered with an occlusive dressing.2  

The differential diagnosis for penny purpura includes lesions that evolve from cupping and coining. Cupping is a type of complementary and alternative medicine that acts by correcting imbalances in the internal biofield and restoring the flow of qi, which determines the state of one's health and life span.4 Cupping is performed by placing a glass cup over a painful body part. A partial vacuum is created by flaming, mechanical withdrawal, or thermal cooling of the entrapped air under the cup. When the flame exhausts the supply of oxygen, the skin is sucked into the mouth of the glass, and the skin is bruised painlessly.4  

The differential also includes child maltreatment syndrome and other disorders that would potentiate bruising. Intravascular etiologies include idiopathic thrombocytopenic purpura, leukemia, coagulation disorders, and other causes of thrombocytopenia or platelet dysfunction.3 Extravascular etiologies include hereditary collagen vascular disease (eg, Ehlers-Danlos syndrome), malnutrition, and other disorders associated with a decrease in collagen and other tissues that support cutaneous vessels. Vascular etiologies include infectious (eg, Rocky Mountain spotted fever, meningococcemia) and noninfectious vasculitis (eg, Henoch-Schönlein purpura), leaky capillary syndrome, drug reactions, and other disorders associated with a loss of vascular integrity.3  

It is important to be able to differentiate self-inflicted lesions in a person who repeatedly acts as if he/she has a physical disorder from those that are created during the practices of cupping or any other cultural healing practice. Vascular disorders, malnutrition, and child abuse also should be excluded.3  

For our patient with factitial purpura, we gently encouraged the family to work with the child's pediatrician and a pediatric psychologist to deal with stress related to the recurrent rash and asked them to think of the rash as a result of an external cause; however, we were careful not to blame anyone for the rash.  

The Diagnosis: Factitial Purpura 

Factitial dermatologic disorders are characterized by skin findings triggered by deliberate manipulation of the skin with objects to create lesions and feign signs of a dermatologic condition to seek emotional and psychological benefit.1 The etiology of the lesions is unclear, and the patient's history of the injury is hollow.2 Most often, there is sudden onset of the lesions without any warning or symptoms. When giving the history, the patient may appear unemotional, does not report pain, and denies self-infliction.1  

In factitial purpura, the purple patches are clearly demarcated from uninvolved skin and have an unusual angular or geometric shape. The pattern typically takes the shape of the object used to create the purpura and lacks the features of recognizable dermatoses.2 In our patient and those with similar linear purpuric streaks, we use the term penny purpura to indicate that the lesions resulted from rubbing with a penny or other blunt object, similar to coining. The lesions occur in areas that are easily accessible and visible such as the arms, chest, or chin. It is suggested that the child unconsciously wants the lesions to be seen. Histologic findings in factitial purpura include disruption of collagen fiber bundles and extravasated red blood cells in the dermis.3 Unfortunately, evolving lesions may give nonspecific histologic findings; when the clinical lesions are typical, skin biopsy usually is unnecessary and may be misleading. Laboratory test results such as complete blood cell count, prothrombin time, and partial thromboplastin time usually are within reference range, as in our patient. 

When evaluating these patients, confrontation is not recommended. More than two-thirds of affected patients have a history of trauma such as sexual/physical abuse or neglect, and the lesions typically arise during times of stress.1,3 Thus, treatment includes nonaccusatory measures and referral for psychologic evaluation. The purpura will rapidly heal when covered with an occlusive dressing.2  

The differential diagnosis for penny purpura includes lesions that evolve from cupping and coining. Cupping is a type of complementary and alternative medicine that acts by correcting imbalances in the internal biofield and restoring the flow of qi, which determines the state of one's health and life span.4 Cupping is performed by placing a glass cup over a painful body part. A partial vacuum is created by flaming, mechanical withdrawal, or thermal cooling of the entrapped air under the cup. When the flame exhausts the supply of oxygen, the skin is sucked into the mouth of the glass, and the skin is bruised painlessly.4  

The differential also includes child maltreatment syndrome and other disorders that would potentiate bruising. Intravascular etiologies include idiopathic thrombocytopenic purpura, leukemia, coagulation disorders, and other causes of thrombocytopenia or platelet dysfunction.3 Extravascular etiologies include hereditary collagen vascular disease (eg, Ehlers-Danlos syndrome), malnutrition, and other disorders associated with a decrease in collagen and other tissues that support cutaneous vessels. Vascular etiologies include infectious (eg, Rocky Mountain spotted fever, meningococcemia) and noninfectious vasculitis (eg, Henoch-Schönlein purpura), leaky capillary syndrome, drug reactions, and other disorders associated with a loss of vascular integrity.3  

It is important to be able to differentiate self-inflicted lesions in a person who repeatedly acts as if he/she has a physical disorder from those that are created during the practices of cupping or any other cultural healing practice. Vascular disorders, malnutrition, and child abuse also should be excluded.3  

For our patient with factitial purpura, we gently encouraged the family to work with the child's pediatrician and a pediatric psychologist to deal with stress related to the recurrent rash and asked them to think of the rash as a result of an external cause; however, we were careful not to blame anyone for the rash.  

References
  1. Harth W, Taube KM, Gieler U. Facticious disorders in dermatology. J Dtsch Dermatol Ges. 2010;8:361-372; quiz 373.  
  2. Al Hawsawi K, Pope E. Pediatric psychocutaneous disorders: a review of primary psychiatric disorders with dermatologic manifestations. Am J Clin Dermatol. 2011;12:247-257.  
  3. Ring HC, Miller IM, Benfeldt E, et al. Artefactual skin lesions in children and adolescents: review of the literature and two cases of factitious purpura. Int J Dermatol. 2015;54:E27-E32. 
  4. Mehta P, Dhapte V. Cupping therapy: a prudent remedy for a plethora of medical ailments. J Tradit Complement Med. 2015;5:127-134. 
References
  1. Harth W, Taube KM, Gieler U. Facticious disorders in dermatology. J Dtsch Dermatol Ges. 2010;8:361-372; quiz 373.  
  2. Al Hawsawi K, Pope E. Pediatric psychocutaneous disorders: a review of primary psychiatric disorders with dermatologic manifestations. Am J Clin Dermatol. 2011;12:247-257.  
  3. Ring HC, Miller IM, Benfeldt E, et al. Artefactual skin lesions in children and adolescents: review of the literature and two cases of factitious purpura. Int J Dermatol. 2015;54:E27-E32. 
  4. Mehta P, Dhapte V. Cupping therapy: a prudent remedy for a plethora of medical ailments. J Tradit Complement Med. 2015;5:127-134. 
Issue
Cutis - 104(1)
Issue
Cutis - 104(1)
Page Number
E8-E9
Page Number
E8-E9
Publications
Publications
Topics
Article Type
Display Headline
Painless Purple Streaks on the Arms and Chest
Display Headline
Painless Purple Streaks on the Arms and Chest
Sections
Questionnaire Body

A 10-year-old boy presented with painless purple streaks on the arms and chest of 2 months' duration. The rash recurred several times per month and cleared without treatment in 3 to 5 days. There was no history of trauma or medication exposure, and he was growing and developing normally. 

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 07/22/2019 - 15:15
Un-Gate On Date
Mon, 07/22/2019 - 15:15
Use ProPublica
CFC Schedule Remove Status
Mon, 07/22/2019 - 15:15
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

Grouped Erythematous Papules and Plaques on the Trunk

Article Type
Changed
Tue, 07/09/2019 - 15:56
Display Headline
Grouped Erythematous Papules and Plaques on the Trunk

The Diagnosis: Cutaneous B-Cell Lymphoma, Follicle Center Subtype 

A 4-mm punch biopsy through the center of the largest lesion on the right posterior shoulder demonstrated a superficial and deep dermal atypical lymphoid infiltrate composed predominantly of small mature lymphocytes with interspersed intermediate-sized cells with irregular to cleaved nuclei, dispersed chromatin, one or more distinct nucleoli, occasional mitoses, and small amounts of cytoplasm (Figure, A). Immunoperoxidase studies showed the infiltrate to be a mixture of CD3+ T cells and CD20+ B cells (Figure, B). The B cells coexpressed B-cell lymphoma (Bcl) 6 protein (Figure, C) but were negative for multiple myeloma 1/interferon regulatory factor 4 and CD10; Bcl2 protein was positive in T cells but inconclusive for staining in B cells. Very few plasma cells were seen with CD138 stain. Fluorescence in situ hybridization studies were negative for IgH and BCL2 gene rearrangement. Molecular diagnostic studies for IgH and κ light chain gene rearrangement were positive for a clonal population. A clonal T-cell receptor γ chain gene rearrangement was not identified. The overall morphologic, immunophenotypic, and molecular findings were consistent with cutaneous involvement by a B-cell lymphoproliferative disorder, favoring primary cutaneous follicle center lymphoma (PCFCL). 

Histopathology of primary cutaneous follicle center lymphoma. A, A superficial and deep dermal atypical lymphoid infiltrate was composed predominantly of small mature lymphocytes with interspersed intermediate-sized cells with irregular to cleaved nuclei, dispersed chromatin, one or more distinct nucleoli, occasional mitoses, and small amounts of cytoplasm (H&E, original magnification ×20 [inset, original magnification ×100). B, Immunoperoxidase study showed CD20+ B cells (original magnification ×20). C, The B cells were coexpressed on B-cell lymphoma 6 immunoperoxidase stain (original magnification ×40).

The patient was referred to our cancer center for further workup consisting of a complete blood cell count with differential; comprehensive metabolic panel; lactate dehydrogenase; serum protein electrophoresis; peripheral blood flow cytometry; and computed tomography of the chest, abdomen, and pelvis. The analysis was unremarkable, supporting primary cutaneous disease. Additional studies suggested in the National Comprehensive Cancer Network (NCCN) Guidelines for primary cutaneous B-cell lymphomas include hepatitis B testing if the patient is being considered for immunotherapy and/or chemotherapy due to risk of reactivation, pregnancy testing in women of childbearing age, and human immunodeficiency virus testing.1 These tests were not performed in our patient because he did not have any risk factors for hepatitis B or human immunodeficiency virus. 

Primary cutaneous B-cell lymphomas originate in the skin without evidence of extracutaneous disease at presentation. They account for approximately 25% of primary cutaneous lymphomas in the United States, with primary cutaneous T-cell lymphoma being most common.2 The revised 2017 World Health Organization classification system defines 3 major subtypes of primary cutaneous B-cell lymphoma (Table).3-9 Primary cutaneous follicle center lymphoma is the most common subtype, accounting for approximately 60% of cases. In Europe, an association with Borrelia burgdorferi has been reported.10 The extent of skin involvement determines the T portion of TNM staging for PCFCL. It is based on the size and location of affected body regions that are delineated, such as the head and neck, chest, abdomen/genitalia, upper back, lower back/buttocks, each upper arm, each lower arm/hand, each upper leg, and each lower leg/foot. T1 is for solitary skin involvement in which the lesion is 5 cm or less in diameter (T1a) or greater than 5 cm (T1b). T2 is for regional skin involvement limited to 1 or 2 contiguous body regions, whereas T2a has all lesions confined to an area 15 cm or less in diameter, T2b has lesions confined to an area greater than 15 cm up to 30 cm in diameter, and the area for T2c is greater than 30 cm in diameter. Finally, T3 is generalized skin involvement, whereas T3a has multiple lesions in 2 noncontiguous body regions, and T3b has multiple lesions on 3 or more regions.11 At presentation, our patient was considered T2cN0M0, as his lesions were present on only 2 contiguous regions extending beyond 30 cm without any evidence of lymph node involvement or metastasis.  

Treatment of PCFCL is tailored to each case, as there is a paucity of randomized data in this rare entity. It is guided by the number and location of cutaneous lesions, associated skin symptoms, age of the patient, and performance status. Local disease can be treated with intralesional corticosteroids, excision, or close monitoring if the patient is asymptomatic. Low-dose radiation therapy may be used as primary treatment or for local recurrence.12 Patients with more extensive skin lesions can relapse after clearing; those with refractory disease can be managed with single-agent rituximab.13 Our patient underwent low-dose radiation therapy with good response and has not experienced recurrence. 

Lymphocytoma cutis, also known as benign reactive lymphoid hyperplasia, can be idiopathic or can arise after arthropod assault, penetrative skin trauma, drugs, or infections. In granuloma annulare, small dermal papules may present in isolation or coalesce to form annular plaques. It is a benign inflammatory disorder of unknown cause, can have mild pruritus, and usually is self-limited. Pyogenic granuloma is a benign vascular proliferation of unknown etiology. Sarcoidosis is an immune-mediated systemic disorder with granuloma formation that has a predilection for the lungs and the skin. 

References
  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Primary Cutaneous B-Cell Lymphomas. Version 2.2018. https://oncolife.com.ua/doc/nccn/Primary_Cutaneous_B-Cell_Lymphomas.pdf. Published January 10, 2018. Accessed June 21, 2019.  
  2. Dores GM, Anderson WF, Devesa SS. Cutaneous lymphomas reported to the National Cancer Institute's surveillance, epidemiology, and end results program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system. J Clin Oncol. 2005;23:7246-7248. 
  3. Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2017. 
  4. Surveillance, Epidemiology, and End Results Program. National Cancer Institute website. https://seer.cancer.gov/. Accessed June 26, 2019. 
  5. Cerroni L. B-cell lymphomas of the skin. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed. China: Elsevier; 2018:2113-2126. 
  6. Jacobsen E, Freedman AS, Willemze R. Primary cutaneous follicle center lymphoma. UpToDate website. https://www.uptodate.com/contents/primary-cutaneous-follicle-center-lymphoma. Updated February 7, 2018. Accessed June 26, 2019. 
  7. Jacobsen E, Freedman AS, Willemze R. Primary cutaneous marginal zone lymphoma. UpToDate website. https://www.uptodate.com/contents/primary-cutaneous-marginal-zone-lymphoma. Updated March 6, 2019. Accessed June 26, 2019. 
  8. Jacobsen E, Freedman AS, Willemze R. Primary cutaneous large B cell lymphoma, leg type. UpToDate website. https://www.uptodate.com/contents/primary-cutaneous-large-b-cell-lymphoma-leg-type. Updated July 3, 2017. Accessed June 26, 2019. 
  9. Suárez AL, Pulitzer M, Horwitz S, et al. Primary cutaneous B-cell lymphomas: part I. clinical features, diagnosis, and classification. J Am Acad Dermatol. 2013;69:329.e1-13; quiz 241-342. 
  10. Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotand. Am J Surg Pathol. 2000;24:1279-1285. 
  11. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:479-484. 
  12. Wilcon RA. Cutaneous B-cell lymphomas: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:1052-1055. 
  13. Morales AV, Advani R, Horwitz SM, et al. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol. 2008;59:953-957.
Article PDF
Author and Disclosure Information

From Roger Williams Medical Center, Providence, Rhode Island. Drs. George and Fischer are from the Division of Dermatology, and Drs. Almardini and Breen are from the Department of Pathology.

The authors report no conflict of interest.

Correspondence: Dean David George, MD, Division of Dermatology, Roger Williams Medical Center, 50 Maude St, 1st Floor, Providence, RI 02908 (ddgeorge@bu.edu).

Issue
Cutis - 104(1)
Publications
Topics
Page Number
25, 30-32
Sections
Author and Disclosure Information

From Roger Williams Medical Center, Providence, Rhode Island. Drs. George and Fischer are from the Division of Dermatology, and Drs. Almardini and Breen are from the Department of Pathology.

The authors report no conflict of interest.

Correspondence: Dean David George, MD, Division of Dermatology, Roger Williams Medical Center, 50 Maude St, 1st Floor, Providence, RI 02908 (ddgeorge@bu.edu).

Author and Disclosure Information

From Roger Williams Medical Center, Providence, Rhode Island. Drs. George and Fischer are from the Division of Dermatology, and Drs. Almardini and Breen are from the Department of Pathology.

The authors report no conflict of interest.

Correspondence: Dean David George, MD, Division of Dermatology, Roger Williams Medical Center, 50 Maude St, 1st Floor, Providence, RI 02908 (ddgeorge@bu.edu).

Article PDF
Article PDF
Related Articles

The Diagnosis: Cutaneous B-Cell Lymphoma, Follicle Center Subtype 

A 4-mm punch biopsy through the center of the largest lesion on the right posterior shoulder demonstrated a superficial and deep dermal atypical lymphoid infiltrate composed predominantly of small mature lymphocytes with interspersed intermediate-sized cells with irregular to cleaved nuclei, dispersed chromatin, one or more distinct nucleoli, occasional mitoses, and small amounts of cytoplasm (Figure, A). Immunoperoxidase studies showed the infiltrate to be a mixture of CD3+ T cells and CD20+ B cells (Figure, B). The B cells coexpressed B-cell lymphoma (Bcl) 6 protein (Figure, C) but were negative for multiple myeloma 1/interferon regulatory factor 4 and CD10; Bcl2 protein was positive in T cells but inconclusive for staining in B cells. Very few plasma cells were seen with CD138 stain. Fluorescence in situ hybridization studies were negative for IgH and BCL2 gene rearrangement. Molecular diagnostic studies for IgH and κ light chain gene rearrangement were positive for a clonal population. A clonal T-cell receptor γ chain gene rearrangement was not identified. The overall morphologic, immunophenotypic, and molecular findings were consistent with cutaneous involvement by a B-cell lymphoproliferative disorder, favoring primary cutaneous follicle center lymphoma (PCFCL). 

Histopathology of primary cutaneous follicle center lymphoma. A, A superficial and deep dermal atypical lymphoid infiltrate was composed predominantly of small mature lymphocytes with interspersed intermediate-sized cells with irregular to cleaved nuclei, dispersed chromatin, one or more distinct nucleoli, occasional mitoses, and small amounts of cytoplasm (H&E, original magnification ×20 [inset, original magnification ×100). B, Immunoperoxidase study showed CD20+ B cells (original magnification ×20). C, The B cells were coexpressed on B-cell lymphoma 6 immunoperoxidase stain (original magnification ×40).

The patient was referred to our cancer center for further workup consisting of a complete blood cell count with differential; comprehensive metabolic panel; lactate dehydrogenase; serum protein electrophoresis; peripheral blood flow cytometry; and computed tomography of the chest, abdomen, and pelvis. The analysis was unremarkable, supporting primary cutaneous disease. Additional studies suggested in the National Comprehensive Cancer Network (NCCN) Guidelines for primary cutaneous B-cell lymphomas include hepatitis B testing if the patient is being considered for immunotherapy and/or chemotherapy due to risk of reactivation, pregnancy testing in women of childbearing age, and human immunodeficiency virus testing.1 These tests were not performed in our patient because he did not have any risk factors for hepatitis B or human immunodeficiency virus. 

Primary cutaneous B-cell lymphomas originate in the skin without evidence of extracutaneous disease at presentation. They account for approximately 25% of primary cutaneous lymphomas in the United States, with primary cutaneous T-cell lymphoma being most common.2 The revised 2017 World Health Organization classification system defines 3 major subtypes of primary cutaneous B-cell lymphoma (Table).3-9 Primary cutaneous follicle center lymphoma is the most common subtype, accounting for approximately 60% of cases. In Europe, an association with Borrelia burgdorferi has been reported.10 The extent of skin involvement determines the T portion of TNM staging for PCFCL. It is based on the size and location of affected body regions that are delineated, such as the head and neck, chest, abdomen/genitalia, upper back, lower back/buttocks, each upper arm, each lower arm/hand, each upper leg, and each lower leg/foot. T1 is for solitary skin involvement in which the lesion is 5 cm or less in diameter (T1a) or greater than 5 cm (T1b). T2 is for regional skin involvement limited to 1 or 2 contiguous body regions, whereas T2a has all lesions confined to an area 15 cm or less in diameter, T2b has lesions confined to an area greater than 15 cm up to 30 cm in diameter, and the area for T2c is greater than 30 cm in diameter. Finally, T3 is generalized skin involvement, whereas T3a has multiple lesions in 2 noncontiguous body regions, and T3b has multiple lesions on 3 or more regions.11 At presentation, our patient was considered T2cN0M0, as his lesions were present on only 2 contiguous regions extending beyond 30 cm without any evidence of lymph node involvement or metastasis.  

Treatment of PCFCL is tailored to each case, as there is a paucity of randomized data in this rare entity. It is guided by the number and location of cutaneous lesions, associated skin symptoms, age of the patient, and performance status. Local disease can be treated with intralesional corticosteroids, excision, or close monitoring if the patient is asymptomatic. Low-dose radiation therapy may be used as primary treatment or for local recurrence.12 Patients with more extensive skin lesions can relapse after clearing; those with refractory disease can be managed with single-agent rituximab.13 Our patient underwent low-dose radiation therapy with good response and has not experienced recurrence. 

Lymphocytoma cutis, also known as benign reactive lymphoid hyperplasia, can be idiopathic or can arise after arthropod assault, penetrative skin trauma, drugs, or infections. In granuloma annulare, small dermal papules may present in isolation or coalesce to form annular plaques. It is a benign inflammatory disorder of unknown cause, can have mild pruritus, and usually is self-limited. Pyogenic granuloma is a benign vascular proliferation of unknown etiology. Sarcoidosis is an immune-mediated systemic disorder with granuloma formation that has a predilection for the lungs and the skin. 

The Diagnosis: Cutaneous B-Cell Lymphoma, Follicle Center Subtype 

A 4-mm punch biopsy through the center of the largest lesion on the right posterior shoulder demonstrated a superficial and deep dermal atypical lymphoid infiltrate composed predominantly of small mature lymphocytes with interspersed intermediate-sized cells with irregular to cleaved nuclei, dispersed chromatin, one or more distinct nucleoli, occasional mitoses, and small amounts of cytoplasm (Figure, A). Immunoperoxidase studies showed the infiltrate to be a mixture of CD3+ T cells and CD20+ B cells (Figure, B). The B cells coexpressed B-cell lymphoma (Bcl) 6 protein (Figure, C) but were negative for multiple myeloma 1/interferon regulatory factor 4 and CD10; Bcl2 protein was positive in T cells but inconclusive for staining in B cells. Very few plasma cells were seen with CD138 stain. Fluorescence in situ hybridization studies were negative for IgH and BCL2 gene rearrangement. Molecular diagnostic studies for IgH and κ light chain gene rearrangement were positive for a clonal population. A clonal T-cell receptor γ chain gene rearrangement was not identified. The overall morphologic, immunophenotypic, and molecular findings were consistent with cutaneous involvement by a B-cell lymphoproliferative disorder, favoring primary cutaneous follicle center lymphoma (PCFCL). 

Histopathology of primary cutaneous follicle center lymphoma. A, A superficial and deep dermal atypical lymphoid infiltrate was composed predominantly of small mature lymphocytes with interspersed intermediate-sized cells with irregular to cleaved nuclei, dispersed chromatin, one or more distinct nucleoli, occasional mitoses, and small amounts of cytoplasm (H&E, original magnification ×20 [inset, original magnification ×100). B, Immunoperoxidase study showed CD20+ B cells (original magnification ×20). C, The B cells were coexpressed on B-cell lymphoma 6 immunoperoxidase stain (original magnification ×40).

The patient was referred to our cancer center for further workup consisting of a complete blood cell count with differential; comprehensive metabolic panel; lactate dehydrogenase; serum protein electrophoresis; peripheral blood flow cytometry; and computed tomography of the chest, abdomen, and pelvis. The analysis was unremarkable, supporting primary cutaneous disease. Additional studies suggested in the National Comprehensive Cancer Network (NCCN) Guidelines for primary cutaneous B-cell lymphomas include hepatitis B testing if the patient is being considered for immunotherapy and/or chemotherapy due to risk of reactivation, pregnancy testing in women of childbearing age, and human immunodeficiency virus testing.1 These tests were not performed in our patient because he did not have any risk factors for hepatitis B or human immunodeficiency virus. 

Primary cutaneous B-cell lymphomas originate in the skin without evidence of extracutaneous disease at presentation. They account for approximately 25% of primary cutaneous lymphomas in the United States, with primary cutaneous T-cell lymphoma being most common.2 The revised 2017 World Health Organization classification system defines 3 major subtypes of primary cutaneous B-cell lymphoma (Table).3-9 Primary cutaneous follicle center lymphoma is the most common subtype, accounting for approximately 60% of cases. In Europe, an association with Borrelia burgdorferi has been reported.10 The extent of skin involvement determines the T portion of TNM staging for PCFCL. It is based on the size and location of affected body regions that are delineated, such as the head and neck, chest, abdomen/genitalia, upper back, lower back/buttocks, each upper arm, each lower arm/hand, each upper leg, and each lower leg/foot. T1 is for solitary skin involvement in which the lesion is 5 cm or less in diameter (T1a) or greater than 5 cm (T1b). T2 is for regional skin involvement limited to 1 or 2 contiguous body regions, whereas T2a has all lesions confined to an area 15 cm or less in diameter, T2b has lesions confined to an area greater than 15 cm up to 30 cm in diameter, and the area for T2c is greater than 30 cm in diameter. Finally, T3 is generalized skin involvement, whereas T3a has multiple lesions in 2 noncontiguous body regions, and T3b has multiple lesions on 3 or more regions.11 At presentation, our patient was considered T2cN0M0, as his lesions were present on only 2 contiguous regions extending beyond 30 cm without any evidence of lymph node involvement or metastasis.  

Treatment of PCFCL is tailored to each case, as there is a paucity of randomized data in this rare entity. It is guided by the number and location of cutaneous lesions, associated skin symptoms, age of the patient, and performance status. Local disease can be treated with intralesional corticosteroids, excision, or close monitoring if the patient is asymptomatic. Low-dose radiation therapy may be used as primary treatment or for local recurrence.12 Patients with more extensive skin lesions can relapse after clearing; those with refractory disease can be managed with single-agent rituximab.13 Our patient underwent low-dose radiation therapy with good response and has not experienced recurrence. 

Lymphocytoma cutis, also known as benign reactive lymphoid hyperplasia, can be idiopathic or can arise after arthropod assault, penetrative skin trauma, drugs, or infections. In granuloma annulare, small dermal papules may present in isolation or coalesce to form annular plaques. It is a benign inflammatory disorder of unknown cause, can have mild pruritus, and usually is self-limited. Pyogenic granuloma is a benign vascular proliferation of unknown etiology. Sarcoidosis is an immune-mediated systemic disorder with granuloma formation that has a predilection for the lungs and the skin. 

References
  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Primary Cutaneous B-Cell Lymphomas. Version 2.2018. https://oncolife.com.ua/doc/nccn/Primary_Cutaneous_B-Cell_Lymphomas.pdf. Published January 10, 2018. Accessed June 21, 2019.  
  2. Dores GM, Anderson WF, Devesa SS. Cutaneous lymphomas reported to the National Cancer Institute's surveillance, epidemiology, and end results program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system. J Clin Oncol. 2005;23:7246-7248. 
  3. Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2017. 
  4. Surveillance, Epidemiology, and End Results Program. National Cancer Institute website. https://seer.cancer.gov/. Accessed June 26, 2019. 
  5. Cerroni L. B-cell lymphomas of the skin. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed. China: Elsevier; 2018:2113-2126. 
  6. Jacobsen E, Freedman AS, Willemze R. Primary cutaneous follicle center lymphoma. UpToDate website. https://www.uptodate.com/contents/primary-cutaneous-follicle-center-lymphoma. Updated February 7, 2018. Accessed June 26, 2019. 
  7. Jacobsen E, Freedman AS, Willemze R. Primary cutaneous marginal zone lymphoma. UpToDate website. https://www.uptodate.com/contents/primary-cutaneous-marginal-zone-lymphoma. Updated March 6, 2019. Accessed June 26, 2019. 
  8. Jacobsen E, Freedman AS, Willemze R. Primary cutaneous large B cell lymphoma, leg type. UpToDate website. https://www.uptodate.com/contents/primary-cutaneous-large-b-cell-lymphoma-leg-type. Updated July 3, 2017. Accessed June 26, 2019. 
  9. Suárez AL, Pulitzer M, Horwitz S, et al. Primary cutaneous B-cell lymphomas: part I. clinical features, diagnosis, and classification. J Am Acad Dermatol. 2013;69:329.e1-13; quiz 241-342. 
  10. Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotand. Am J Surg Pathol. 2000;24:1279-1285. 
  11. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:479-484. 
  12. Wilcon RA. Cutaneous B-cell lymphomas: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:1052-1055. 
  13. Morales AV, Advani R, Horwitz SM, et al. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol. 2008;59:953-957.
References
  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Primary Cutaneous B-Cell Lymphomas. Version 2.2018. https://oncolife.com.ua/doc/nccn/Primary_Cutaneous_B-Cell_Lymphomas.pdf. Published January 10, 2018. Accessed June 21, 2019.  
  2. Dores GM, Anderson WF, Devesa SS. Cutaneous lymphomas reported to the National Cancer Institute's surveillance, epidemiology, and end results program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system. J Clin Oncol. 2005;23:7246-7248. 
  3. Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2017. 
  4. Surveillance, Epidemiology, and End Results Program. National Cancer Institute website. https://seer.cancer.gov/. Accessed June 26, 2019. 
  5. Cerroni L. B-cell lymphomas of the skin. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed. China: Elsevier; 2018:2113-2126. 
  6. Jacobsen E, Freedman AS, Willemze R. Primary cutaneous follicle center lymphoma. UpToDate website. https://www.uptodate.com/contents/primary-cutaneous-follicle-center-lymphoma. Updated February 7, 2018. Accessed June 26, 2019. 
  7. Jacobsen E, Freedman AS, Willemze R. Primary cutaneous marginal zone lymphoma. UpToDate website. https://www.uptodate.com/contents/primary-cutaneous-marginal-zone-lymphoma. Updated March 6, 2019. Accessed June 26, 2019. 
  8. Jacobsen E, Freedman AS, Willemze R. Primary cutaneous large B cell lymphoma, leg type. UpToDate website. https://www.uptodate.com/contents/primary-cutaneous-large-b-cell-lymphoma-leg-type. Updated July 3, 2017. Accessed June 26, 2019. 
  9. Suárez AL, Pulitzer M, Horwitz S, et al. Primary cutaneous B-cell lymphomas: part I. clinical features, diagnosis, and classification. J Am Acad Dermatol. 2013;69:329.e1-13; quiz 241-342. 
  10. Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotand. Am J Surg Pathol. 2000;24:1279-1285. 
  11. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:479-484. 
  12. Wilcon RA. Cutaneous B-cell lymphomas: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:1052-1055. 
  13. Morales AV, Advani R, Horwitz SM, et al. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol. 2008;59:953-957.
Issue
Cutis - 104(1)
Issue
Cutis - 104(1)
Page Number
25, 30-32
Page Number
25, 30-32
Publications
Publications
Topics
Article Type
Display Headline
Grouped Erythematous Papules and Plaques on the Trunk
Display Headline
Grouped Erythematous Papules and Plaques on the Trunk
Sections
Questionnaire Body

A 34-year-old man presented to the outpatient dermatology clinic with 3 groups of mildly pruritic, erythematous papules and plaques. The most prominent group appeared on the right posterior shoulder and had been slowly enlarging in size over the last 12 months (quiz image). A similar thinner group appeared on the left mid-back 6 months prior, and a third smaller group appeared over the left serratus anterior muscle 2 months prior. The patient reported having similar episodes dating back to his early 20s. In those instances, the lesions presented without an inciting incident, became more pronounced, and persisted for months to years before resolving. Previously affected areas included the upper and lateral back, flanks, and posterior upper arms. The patient used triamcinolone cream 0.1% up to 3 times daily on active lesions, which improved the pruritus and seemed to make the lesions resolve more quickly. He denied fever, chills, night sweats, anorexia, weight loss, fatigue, cough, and shortness of breath. His only medication was ranitidine 150 mg twice daily for gastroesophageal reflux disease. Physical examination revealed no palpable lymphadenopathy.

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 07/08/2019 - 12:45
Un-Gate On Date
Mon, 07/08/2019 - 12:45
Use ProPublica
CFC Schedule Remove Status
Mon, 07/08/2019 - 12:45
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

Rapidly Enlarging Neoplasm on the Face

Article Type
Changed
Mon, 07/01/2019 - 16:20
Display Headline
Rapidly Enlarging Neoplasm on the Face

The Diagnosis: Atypical Fibroxanthoma  

Shave biopsy showed the superficial aspect of a highly cellular tumor composed of pleomorphic spindle cells exhibiting storiform growth and increased mitotic activity (Figure 1). The tumor stained positive for factor XIIIa, CD163, CD68, and smooth muscle actin (mild), and negative for high-molecular-weight cytokeratin (HMW-CK), p63, S-100, and melan-A. Subsequent excision with 0.5-cm margins was performed, and histopathology showed a well-circumscribed tumor contained within the dermis with a histologic scar at the outer margin (Figure 2). There was no lymphovascular or perineural invasion by tumor cells. Re-excision with 0.3-cm margins demonstrated no residual scar or tumor, and external radiation was deferred due to clear surgical margins.  

Figure 1. Atypical fibroxanthoma. A, Highly cellular tumor composed of pleomorphic spindle cells exhibiting storiform growth and increased mitotic activity (H&E, original magnification ×10). B, High-power view of tumor (H&E, original magnification ×20).

Figure 2. Atypical fibroxanthoma. Excision of the nodule showed a well-circumscribed, dermally based tumor without subcutaneous invasion (H&E, original magnification ×4).

Atypical fibroxanthoma (AFX) belongs to a group of spindle cell neoplasms that can be diagnostically challenging, as they often lack specific morphologic features on examination or routine histology. These neoplasms--of which the differential includes malignant fibrous histiocytoma, spindle cell squamous cell carcinoma (SCC), desmoplastic melanoma, and leiomyosarcoma--may each appear as a rapidly enlarging solitary plaque or nodule on sun-damaged skin on the head and neck or less commonly on the trunk, arms, or legs. Histologically, the cells of AFX exhibit notable pleomorphism with frequent atypical mitotic figures and nonspecific surrounding dermal changes. Subcutaneous and lymphovascular or perineural invasion of tumor cells can point away from the diagnosis of AFX; however, these features are likely to be missed in small superficial shave biopsies.1,2 Therefore, immunohistochemistry (IHC) and adequate tumor sampling are essential in the accurate diagnosis of AFX and other spindle cell neoplasms.  

Several IHC markers have been employed in differentiating AFX from other spindle cell neoplasms.3-8 Positive stains for AFX include factor XIIIa (10%-25%), vimentin (>99%), CD10 (95%-100%), procollagen (87%), CD99 (35%-73%), CD163 (37%-79%), smooth muscle actin (50%), CD68 (>50%), and CD31 (43%). Other stains, such as HMW-CK, S-100, p63, desmin, CD34, and melan-A, typically are negative in AFX but are actively expressed in other pleomorphic spindle cell tumors. The Table summarizes the utility of these various markers in narrowing the differential diagnosis of a spindle cell lesion. Selection of an appropriate panel of IHC markers is critical for accurate diagnosis of AFX and exclusion of more aggressive, poorly differentiated spindle cell neoplasms. Key IHC markers include S-100 (negative in AFX; positive in desmoplastic melanoma), HMW-CK (negative in AFX; positive in spindle cell SCC), and p63 (negative in AFX; positive in spindle cell SCC). Benoit et al9 reported a case of a poorly differentiated spindle cell SCC misdiagnosed as AFX based on a limited IHC panel that was negative for pancytokeratin and S-100. Later, a more comprehensive IHC panel including HMW-CK and p63 confirmed spindle cell SCC, but by this time, a delay in therapy had allowed the tumor to metastasize, which ultimately proved fatal to the patient.9  

In addition to incomplete IHC evaluation, accurate diagnosis of spindle cell tumors also may be obscured by inadequate tumor sampling. The cells of AFX tumors often are well circumscribed and dermally based, and an excisional biopsy is the preferred biopsy procedure for AFX. A tumor invading into subcutaneous tissue or into lymphovascular or perineural structures suggests a more aggressive, poorly differentiated spindle cell neoplasm.1,3 For example, the tumor cells of malignant fibrous histiocytoma, which belongs to the undifferentiated pleomorphic sarcoma group, may appear identical to those of AFX on histology, and the 2 tumors display similar IHC profiles.3 Malignant fibrous histiocytoma, however, extends into the subcutaneous space and portends a notably worse prognosis compared to AFX. Malignant fibrous histiocytoma tumors therefore require more aggressive treatment strategies such as external beam radiation therapy, whereas AFX can be safely treated with surgical removal alone. In our patient, complete visualization of tumor margins solidified the diagnosis of AFX and spared our patient from unnecessary radiation therapy. Overall, AFX has a good prognosis and metastasis is rare, particularly when good margin control is achieved.10 

Our case highlights the importance of clinicopathologic correlation, including appropriate IHC analysis and adequate tumor sampling in the diagnostic workup of a pleomorphic spindle cell neoplasm. Although these tumors are well studied, their notable degree of clinical and histologic heterogeneity may pose a diagnostic challenge to even experienced dermatologists and require careful consideration of the potential pitfalls in diagnosis.  

References
  1. Iorizzo LJ, Brown MD. Atypical fibroxanthoma: a review of the literature. Dermatol Surg. 2011;37:146-157.  
  2. Lopez L, Velez R. Atypical fibroxanthoma. Arch Pathol Lab Med. 2016;140:376-379.  
  3. Hussein MR. Atypical fibroxanthoma: new insights. Expert Rev Anticancer Ther. 2014;14:1075-1088.  
  4. Gleason BC, Calder KB, Cibull TL, et al. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma. J Cutan Pathol. 2009;36:543-547.  
  5. Pouryazdanparast P, Yu L, Cutland JE, et al. Diagnostic value of CD163 in cutaneous spindle cell lesions. J Cutan Pathol. 2009;36:859-864. 
  6. Beer TW. CD163 is not a sensitive marker for identification of atypical fibroxanthoma. J Cutan Pathol. 2012;39:29-32.  
  7. Longacre TA, Smoller BR, Rouse RV. Atypical fibroxanthoma. multiple immunohistologic profiles. Am J Surg Pathol. 1993;17:1199-1209. 
  8. Altman DA, Nickoloff BD, Fivenson DP. Differential expression of factor XIIa and CD34 in cutaneous mesenchymal tumors. J Cutan Pathol. 1993;20:154-158.  
  9. Benoit A, Wisell J, Brown M. Cutaneous spindle cell carcinoma misdiagnosed as atypical fibroxanthoma based on immunohistochemical stains. JAAD Case Rep. 2015;1:392-394.  
  10. New D, Bahrami S, Malone J, et al. Atypical fibroxanthoma with regional lymph node metastasis: report of a case and review of the literature. Arch Dermatol. 2010;146:1399-1404. 
Article PDF
Author and Disclosure Information

Dr. Menge is from Harvard Combined Dermatology Residency Training Program, Boston, Massachusetts. Drs. Hibler, Busam, and Rossi are from Memorial Sloan Kettering Cancer Center, New York, New York. Dr. Mack is from GlamDerm Skin Care Center, New York.

The authors report no conflict of interest.

This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. Correspondence: Tyler D. Menge, MD, Harvard Combined Dermatology Residency Training Program, 55 Fruit St, Boston, MA 02114 (tyler.menge@gmail.com).

Issue
Cutis - 103(6)
Publications
Topics
Page Number
E28-E30
Sections
Author and Disclosure Information

Dr. Menge is from Harvard Combined Dermatology Residency Training Program, Boston, Massachusetts. Drs. Hibler, Busam, and Rossi are from Memorial Sloan Kettering Cancer Center, New York, New York. Dr. Mack is from GlamDerm Skin Care Center, New York.

The authors report no conflict of interest.

This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. Correspondence: Tyler D. Menge, MD, Harvard Combined Dermatology Residency Training Program, 55 Fruit St, Boston, MA 02114 (tyler.menge@gmail.com).

Author and Disclosure Information

Dr. Menge is from Harvard Combined Dermatology Residency Training Program, Boston, Massachusetts. Drs. Hibler, Busam, and Rossi are from Memorial Sloan Kettering Cancer Center, New York, New York. Dr. Mack is from GlamDerm Skin Care Center, New York.

The authors report no conflict of interest.

This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. Correspondence: Tyler D. Menge, MD, Harvard Combined Dermatology Residency Training Program, 55 Fruit St, Boston, MA 02114 (tyler.menge@gmail.com).

Article PDF
Article PDF
Related Articles

The Diagnosis: Atypical Fibroxanthoma  

Shave biopsy showed the superficial aspect of a highly cellular tumor composed of pleomorphic spindle cells exhibiting storiform growth and increased mitotic activity (Figure 1). The tumor stained positive for factor XIIIa, CD163, CD68, and smooth muscle actin (mild), and negative for high-molecular-weight cytokeratin (HMW-CK), p63, S-100, and melan-A. Subsequent excision with 0.5-cm margins was performed, and histopathology showed a well-circumscribed tumor contained within the dermis with a histologic scar at the outer margin (Figure 2). There was no lymphovascular or perineural invasion by tumor cells. Re-excision with 0.3-cm margins demonstrated no residual scar or tumor, and external radiation was deferred due to clear surgical margins.  

Figure 1. Atypical fibroxanthoma. A, Highly cellular tumor composed of pleomorphic spindle cells exhibiting storiform growth and increased mitotic activity (H&E, original magnification ×10). B, High-power view of tumor (H&E, original magnification ×20).

Figure 2. Atypical fibroxanthoma. Excision of the nodule showed a well-circumscribed, dermally based tumor without subcutaneous invasion (H&E, original magnification ×4).

Atypical fibroxanthoma (AFX) belongs to a group of spindle cell neoplasms that can be diagnostically challenging, as they often lack specific morphologic features on examination or routine histology. These neoplasms--of which the differential includes malignant fibrous histiocytoma, spindle cell squamous cell carcinoma (SCC), desmoplastic melanoma, and leiomyosarcoma--may each appear as a rapidly enlarging solitary plaque or nodule on sun-damaged skin on the head and neck or less commonly on the trunk, arms, or legs. Histologically, the cells of AFX exhibit notable pleomorphism with frequent atypical mitotic figures and nonspecific surrounding dermal changes. Subcutaneous and lymphovascular or perineural invasion of tumor cells can point away from the diagnosis of AFX; however, these features are likely to be missed in small superficial shave biopsies.1,2 Therefore, immunohistochemistry (IHC) and adequate tumor sampling are essential in the accurate diagnosis of AFX and other spindle cell neoplasms.  

Several IHC markers have been employed in differentiating AFX from other spindle cell neoplasms.3-8 Positive stains for AFX include factor XIIIa (10%-25%), vimentin (>99%), CD10 (95%-100%), procollagen (87%), CD99 (35%-73%), CD163 (37%-79%), smooth muscle actin (50%), CD68 (>50%), and CD31 (43%). Other stains, such as HMW-CK, S-100, p63, desmin, CD34, and melan-A, typically are negative in AFX but are actively expressed in other pleomorphic spindle cell tumors. The Table summarizes the utility of these various markers in narrowing the differential diagnosis of a spindle cell lesion. Selection of an appropriate panel of IHC markers is critical for accurate diagnosis of AFX and exclusion of more aggressive, poorly differentiated spindle cell neoplasms. Key IHC markers include S-100 (negative in AFX; positive in desmoplastic melanoma), HMW-CK (negative in AFX; positive in spindle cell SCC), and p63 (negative in AFX; positive in spindle cell SCC). Benoit et al9 reported a case of a poorly differentiated spindle cell SCC misdiagnosed as AFX based on a limited IHC panel that was negative for pancytokeratin and S-100. Later, a more comprehensive IHC panel including HMW-CK and p63 confirmed spindle cell SCC, but by this time, a delay in therapy had allowed the tumor to metastasize, which ultimately proved fatal to the patient.9  

In addition to incomplete IHC evaluation, accurate diagnosis of spindle cell tumors also may be obscured by inadequate tumor sampling. The cells of AFX tumors often are well circumscribed and dermally based, and an excisional biopsy is the preferred biopsy procedure for AFX. A tumor invading into subcutaneous tissue or into lymphovascular or perineural structures suggests a more aggressive, poorly differentiated spindle cell neoplasm.1,3 For example, the tumor cells of malignant fibrous histiocytoma, which belongs to the undifferentiated pleomorphic sarcoma group, may appear identical to those of AFX on histology, and the 2 tumors display similar IHC profiles.3 Malignant fibrous histiocytoma, however, extends into the subcutaneous space and portends a notably worse prognosis compared to AFX. Malignant fibrous histiocytoma tumors therefore require more aggressive treatment strategies such as external beam radiation therapy, whereas AFX can be safely treated with surgical removal alone. In our patient, complete visualization of tumor margins solidified the diagnosis of AFX and spared our patient from unnecessary radiation therapy. Overall, AFX has a good prognosis and metastasis is rare, particularly when good margin control is achieved.10 

Our case highlights the importance of clinicopathologic correlation, including appropriate IHC analysis and adequate tumor sampling in the diagnostic workup of a pleomorphic spindle cell neoplasm. Although these tumors are well studied, their notable degree of clinical and histologic heterogeneity may pose a diagnostic challenge to even experienced dermatologists and require careful consideration of the potential pitfalls in diagnosis.  

The Diagnosis: Atypical Fibroxanthoma  

Shave biopsy showed the superficial aspect of a highly cellular tumor composed of pleomorphic spindle cells exhibiting storiform growth and increased mitotic activity (Figure 1). The tumor stained positive for factor XIIIa, CD163, CD68, and smooth muscle actin (mild), and negative for high-molecular-weight cytokeratin (HMW-CK), p63, S-100, and melan-A. Subsequent excision with 0.5-cm margins was performed, and histopathology showed a well-circumscribed tumor contained within the dermis with a histologic scar at the outer margin (Figure 2). There was no lymphovascular or perineural invasion by tumor cells. Re-excision with 0.3-cm margins demonstrated no residual scar or tumor, and external radiation was deferred due to clear surgical margins.  

Figure 1. Atypical fibroxanthoma. A, Highly cellular tumor composed of pleomorphic spindle cells exhibiting storiform growth and increased mitotic activity (H&E, original magnification ×10). B, High-power view of tumor (H&E, original magnification ×20).

Figure 2. Atypical fibroxanthoma. Excision of the nodule showed a well-circumscribed, dermally based tumor without subcutaneous invasion (H&E, original magnification ×4).

Atypical fibroxanthoma (AFX) belongs to a group of spindle cell neoplasms that can be diagnostically challenging, as they often lack specific morphologic features on examination or routine histology. These neoplasms--of which the differential includes malignant fibrous histiocytoma, spindle cell squamous cell carcinoma (SCC), desmoplastic melanoma, and leiomyosarcoma--may each appear as a rapidly enlarging solitary plaque or nodule on sun-damaged skin on the head and neck or less commonly on the trunk, arms, or legs. Histologically, the cells of AFX exhibit notable pleomorphism with frequent atypical mitotic figures and nonspecific surrounding dermal changes. Subcutaneous and lymphovascular or perineural invasion of tumor cells can point away from the diagnosis of AFX; however, these features are likely to be missed in small superficial shave biopsies.1,2 Therefore, immunohistochemistry (IHC) and adequate tumor sampling are essential in the accurate diagnosis of AFX and other spindle cell neoplasms.  

Several IHC markers have been employed in differentiating AFX from other spindle cell neoplasms.3-8 Positive stains for AFX include factor XIIIa (10%-25%), vimentin (>99%), CD10 (95%-100%), procollagen (87%), CD99 (35%-73%), CD163 (37%-79%), smooth muscle actin (50%), CD68 (>50%), and CD31 (43%). Other stains, such as HMW-CK, S-100, p63, desmin, CD34, and melan-A, typically are negative in AFX but are actively expressed in other pleomorphic spindle cell tumors. The Table summarizes the utility of these various markers in narrowing the differential diagnosis of a spindle cell lesion. Selection of an appropriate panel of IHC markers is critical for accurate diagnosis of AFX and exclusion of more aggressive, poorly differentiated spindle cell neoplasms. Key IHC markers include S-100 (negative in AFX; positive in desmoplastic melanoma), HMW-CK (negative in AFX; positive in spindle cell SCC), and p63 (negative in AFX; positive in spindle cell SCC). Benoit et al9 reported a case of a poorly differentiated spindle cell SCC misdiagnosed as AFX based on a limited IHC panel that was negative for pancytokeratin and S-100. Later, a more comprehensive IHC panel including HMW-CK and p63 confirmed spindle cell SCC, but by this time, a delay in therapy had allowed the tumor to metastasize, which ultimately proved fatal to the patient.9  

In addition to incomplete IHC evaluation, accurate diagnosis of spindle cell tumors also may be obscured by inadequate tumor sampling. The cells of AFX tumors often are well circumscribed and dermally based, and an excisional biopsy is the preferred biopsy procedure for AFX. A tumor invading into subcutaneous tissue or into lymphovascular or perineural structures suggests a more aggressive, poorly differentiated spindle cell neoplasm.1,3 For example, the tumor cells of malignant fibrous histiocytoma, which belongs to the undifferentiated pleomorphic sarcoma group, may appear identical to those of AFX on histology, and the 2 tumors display similar IHC profiles.3 Malignant fibrous histiocytoma, however, extends into the subcutaneous space and portends a notably worse prognosis compared to AFX. Malignant fibrous histiocytoma tumors therefore require more aggressive treatment strategies such as external beam radiation therapy, whereas AFX can be safely treated with surgical removal alone. In our patient, complete visualization of tumor margins solidified the diagnosis of AFX and spared our patient from unnecessary radiation therapy. Overall, AFX has a good prognosis and metastasis is rare, particularly when good margin control is achieved.10 

Our case highlights the importance of clinicopathologic correlation, including appropriate IHC analysis and adequate tumor sampling in the diagnostic workup of a pleomorphic spindle cell neoplasm. Although these tumors are well studied, their notable degree of clinical and histologic heterogeneity may pose a diagnostic challenge to even experienced dermatologists and require careful consideration of the potential pitfalls in diagnosis.  

References
  1. Iorizzo LJ, Brown MD. Atypical fibroxanthoma: a review of the literature. Dermatol Surg. 2011;37:146-157.  
  2. Lopez L, Velez R. Atypical fibroxanthoma. Arch Pathol Lab Med. 2016;140:376-379.  
  3. Hussein MR. Atypical fibroxanthoma: new insights. Expert Rev Anticancer Ther. 2014;14:1075-1088.  
  4. Gleason BC, Calder KB, Cibull TL, et al. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma. J Cutan Pathol. 2009;36:543-547.  
  5. Pouryazdanparast P, Yu L, Cutland JE, et al. Diagnostic value of CD163 in cutaneous spindle cell lesions. J Cutan Pathol. 2009;36:859-864. 
  6. Beer TW. CD163 is not a sensitive marker for identification of atypical fibroxanthoma. J Cutan Pathol. 2012;39:29-32.  
  7. Longacre TA, Smoller BR, Rouse RV. Atypical fibroxanthoma. multiple immunohistologic profiles. Am J Surg Pathol. 1993;17:1199-1209. 
  8. Altman DA, Nickoloff BD, Fivenson DP. Differential expression of factor XIIa and CD34 in cutaneous mesenchymal tumors. J Cutan Pathol. 1993;20:154-158.  
  9. Benoit A, Wisell J, Brown M. Cutaneous spindle cell carcinoma misdiagnosed as atypical fibroxanthoma based on immunohistochemical stains. JAAD Case Rep. 2015;1:392-394.  
  10. New D, Bahrami S, Malone J, et al. Atypical fibroxanthoma with regional lymph node metastasis: report of a case and review of the literature. Arch Dermatol. 2010;146:1399-1404. 
References
  1. Iorizzo LJ, Brown MD. Atypical fibroxanthoma: a review of the literature. Dermatol Surg. 2011;37:146-157.  
  2. Lopez L, Velez R. Atypical fibroxanthoma. Arch Pathol Lab Med. 2016;140:376-379.  
  3. Hussein MR. Atypical fibroxanthoma: new insights. Expert Rev Anticancer Ther. 2014;14:1075-1088.  
  4. Gleason BC, Calder KB, Cibull TL, et al. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma. J Cutan Pathol. 2009;36:543-547.  
  5. Pouryazdanparast P, Yu L, Cutland JE, et al. Diagnostic value of CD163 in cutaneous spindle cell lesions. J Cutan Pathol. 2009;36:859-864. 
  6. Beer TW. CD163 is not a sensitive marker for identification of atypical fibroxanthoma. J Cutan Pathol. 2012;39:29-32.  
  7. Longacre TA, Smoller BR, Rouse RV. Atypical fibroxanthoma. multiple immunohistologic profiles. Am J Surg Pathol. 1993;17:1199-1209. 
  8. Altman DA, Nickoloff BD, Fivenson DP. Differential expression of factor XIIa and CD34 in cutaneous mesenchymal tumors. J Cutan Pathol. 1993;20:154-158.  
  9. Benoit A, Wisell J, Brown M. Cutaneous spindle cell carcinoma misdiagnosed as atypical fibroxanthoma based on immunohistochemical stains. JAAD Case Rep. 2015;1:392-394.  
  10. New D, Bahrami S, Malone J, et al. Atypical fibroxanthoma with regional lymph node metastasis: report of a case and review of the literature. Arch Dermatol. 2010;146:1399-1404. 
Issue
Cutis - 103(6)
Issue
Cutis - 103(6)
Page Number
E28-E30
Page Number
E28-E30
Publications
Publications
Topics
Article Type
Display Headline
Rapidly Enlarging Neoplasm on the Face
Display Headline
Rapidly Enlarging Neoplasm on the Face
Sections
Questionnaire Body

An 88-year-old woman presented for evaluation of an asymptomatic facial lesion that she first noticed 3 months prior, with rapid growth over the last month. Review of systems was negative, and she denied any history of connective tissue disease, skin cancer, or radiation to the head or neck area. Physical examination revealed a 1.5-cm, solitary, violaceous nodule on the left lateral eyebrow on a background of actinically damaged skin. The lesion was nontender and there were no similar lesions or palpable lymphadenopathy.

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 07/01/2019 - 15:30
Un-Gate On Date
Mon, 07/01/2019 - 15:30
Use ProPublica
CFC Schedule Remove Status
Mon, 07/01/2019 - 15:30
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

Recurrent Pruritic Multifocal Erythematous Rash

Article Type
Changed
Tue, 06/25/2019 - 14:51
Display Headline
Recurrent Pruritic Multifocal Erythematous Rash

The Diagnosis: Wells Syndrome 

Histopathologic examination of the biopsy demonstrated overlying acanthosis, focal spongiosis, and exocytosis. There also was proliferation and thickening of superficial capillaries and papillary fibrosis (Figure, A). There was a mixed interstitial and perivascular inflammatory infiltrate consisting of lymphocytes, histiocytes, plasma cells, and eosinophils (Figure, A and B). Occasional flame figures were identified (Figure, C). 

Wells syndrome. A, Histopathologic examination showed thickening of superficial capillaries and papillary fibrosis (H&E, original magnification ×4). B, There was a mixed interstitial and perivascular inflammatory infiltrate consisting of lymphocytes, histiocytes, plasma cells, and eosinophils (H&E, original magnification ×20). C, Occasional flame figures were identified (H&E, original magnification ×40).

Wells syndrome, also known as eosinophilic cellulitis, was first described in 1971 by Wells1 as a recurrent granulomatous dermatitis with eosinophilia. Rarely reported worldwide, this chronic relapsing condition is characterized by a pronounced eosinophilic infiltrate of the dermis resembling urticaria or cellulitis.2 The exact etiology has not been elucidated; however, links to certain medications, vaccines, exaggerated arthropod reactions, infections, and malignancies have been documented.3  

Wells syndrome is a diagnosis of exclusion and lacks a predictable dermatologic presentation, thereby mandating focused clinical follow-up as well as correlation with histopathology findings. Although the classic histologic hallmark of Wells syndrome is scattered flame figures, this finding is not specific and can be found in other hypereosinophilic conditions.2 Clinical manifestations most often consist of 2 distinct phases: an initial painful burning or pruritic sensation, followed by the development of erythematous and edematous dermal plaques that may heal with slight hyperpigmentation over 4 to 8 weeks. A case series of 19 patients demonstrated variants of Wells syndrome, with an annular granuloma-like appearance found primarily in adults and the signature plaque-type appearance predominating in children.4  

Acute urticaria is characterized by pruritic erythematous wheals secondary to a histamine-mediated response brought on by a variety of triggers, typically allergic and self-resolving within 24 hours. When such lesions last longer than 24 hours, biopsy should be performed to exclude urticarial vasculitis, which is characterized by a burning or painful sensation rather than pruritis, in addition to dermal neutrophilia and perivascular infiltrate on histology. Erythema migrans of Lyme disease begins at the site of a tick bite, evolving from a red macule to an expanding targetoid lesion and typically is not pruritic. Infectious cellulitis presents with warm, tender, and poorly defined erythematous patches; can progress rapidly; and is accompanied by systemic symptoms such as fevers, malaise, and lymphadenopathy.  

Best evidence favors the use of moderate- to high-dose corticosteroids as first-line treatment.5 The use of tumor necrosis factor blockers, various immunomodulating agents, and combination therapy with levocetirizine and hydroxyzine have demonstrated variable levels of efficacy, albeit often followed by high rates of relapse with drug discontinuation.6  

References
  1. Wells GC. Recurrent granulomatous dermatitis with eosinophilia. Trans St Johns Hosp Dermatol Soc. 1971;57:46-56. 
  2. Aberer W, Konrad K, Wolff K. Wells' syndrome is a distinctive disease entity and not a histologic diagnosis. J Am Acad Dermatol. 1988;18:105-114. 
  3. Kaufmann D, Pichler W, Beer JH. Severe episode of high fever with rash, lymphadenopathy, neutropenia, and eosinophilia after minocycline therapy for acne. Arch Intern Med. 1994;154:1983-1984. 
  4. Caputo R, Marzano AV, Vezzoli P, et al. Wells syndrome in adults and children: a report of 19 cases. Arch Dermatol. 2006;142:1157-1161. 
  5. Ferreli C, Pinna AL, Atzori L, et al. Eosinophilic cellulitis (Well's syndrome): a new case description. J Eur Acad Dermatol Venereol. 1999;13:41-45. 
  6. Cormerais M, Poizeau F, Darrieux L, et al. Wells' syndrome mimicking facial cellulitis: a report of two cases. Case Rep Dermatol. 2015;7:117-122.
Article PDF
Author and Disclosure Information

Dr. C. Albornoz is from Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania. Dr. Benedetto is from Crozer-Keystone Health System, Drexel Hill, Pennsylvania. Dr. M.A. Albornoz is from Riddle Memorial Hospital, Media, Pennsylvania.

The authors report no conflict of interest.

Correspondence: Christian Albornoz, MD, 833 Chestnut St, Ste 740, Philadelphia, PA 19107 (Tuf41589@temple.edu).

Issue
Cutis - 103(6)
Publications
Topics
Page Number
E25-E27
Sections
Author and Disclosure Information

Dr. C. Albornoz is from Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania. Dr. Benedetto is from Crozer-Keystone Health System, Drexel Hill, Pennsylvania. Dr. M.A. Albornoz is from Riddle Memorial Hospital, Media, Pennsylvania.

The authors report no conflict of interest.

Correspondence: Christian Albornoz, MD, 833 Chestnut St, Ste 740, Philadelphia, PA 19107 (Tuf41589@temple.edu).

Author and Disclosure Information

Dr. C. Albornoz is from Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania. Dr. Benedetto is from Crozer-Keystone Health System, Drexel Hill, Pennsylvania. Dr. M.A. Albornoz is from Riddle Memorial Hospital, Media, Pennsylvania.

The authors report no conflict of interest.

Correspondence: Christian Albornoz, MD, 833 Chestnut St, Ste 740, Philadelphia, PA 19107 (Tuf41589@temple.edu).

Article PDF
Article PDF
Related Articles

The Diagnosis: Wells Syndrome 

Histopathologic examination of the biopsy demonstrated overlying acanthosis, focal spongiosis, and exocytosis. There also was proliferation and thickening of superficial capillaries and papillary fibrosis (Figure, A). There was a mixed interstitial and perivascular inflammatory infiltrate consisting of lymphocytes, histiocytes, plasma cells, and eosinophils (Figure, A and B). Occasional flame figures were identified (Figure, C). 

Wells syndrome. A, Histopathologic examination showed thickening of superficial capillaries and papillary fibrosis (H&E, original magnification ×4). B, There was a mixed interstitial and perivascular inflammatory infiltrate consisting of lymphocytes, histiocytes, plasma cells, and eosinophils (H&E, original magnification ×20). C, Occasional flame figures were identified (H&E, original magnification ×40).

Wells syndrome, also known as eosinophilic cellulitis, was first described in 1971 by Wells1 as a recurrent granulomatous dermatitis with eosinophilia. Rarely reported worldwide, this chronic relapsing condition is characterized by a pronounced eosinophilic infiltrate of the dermis resembling urticaria or cellulitis.2 The exact etiology has not been elucidated; however, links to certain medications, vaccines, exaggerated arthropod reactions, infections, and malignancies have been documented.3  

Wells syndrome is a diagnosis of exclusion and lacks a predictable dermatologic presentation, thereby mandating focused clinical follow-up as well as correlation with histopathology findings. Although the classic histologic hallmark of Wells syndrome is scattered flame figures, this finding is not specific and can be found in other hypereosinophilic conditions.2 Clinical manifestations most often consist of 2 distinct phases: an initial painful burning or pruritic sensation, followed by the development of erythematous and edematous dermal plaques that may heal with slight hyperpigmentation over 4 to 8 weeks. A case series of 19 patients demonstrated variants of Wells syndrome, with an annular granuloma-like appearance found primarily in adults and the signature plaque-type appearance predominating in children.4  

Acute urticaria is characterized by pruritic erythematous wheals secondary to a histamine-mediated response brought on by a variety of triggers, typically allergic and self-resolving within 24 hours. When such lesions last longer than 24 hours, biopsy should be performed to exclude urticarial vasculitis, which is characterized by a burning or painful sensation rather than pruritis, in addition to dermal neutrophilia and perivascular infiltrate on histology. Erythema migrans of Lyme disease begins at the site of a tick bite, evolving from a red macule to an expanding targetoid lesion and typically is not pruritic. Infectious cellulitis presents with warm, tender, and poorly defined erythematous patches; can progress rapidly; and is accompanied by systemic symptoms such as fevers, malaise, and lymphadenopathy.  

Best evidence favors the use of moderate- to high-dose corticosteroids as first-line treatment.5 The use of tumor necrosis factor blockers, various immunomodulating agents, and combination therapy with levocetirizine and hydroxyzine have demonstrated variable levels of efficacy, albeit often followed by high rates of relapse with drug discontinuation.6  

The Diagnosis: Wells Syndrome 

Histopathologic examination of the biopsy demonstrated overlying acanthosis, focal spongiosis, and exocytosis. There also was proliferation and thickening of superficial capillaries and papillary fibrosis (Figure, A). There was a mixed interstitial and perivascular inflammatory infiltrate consisting of lymphocytes, histiocytes, plasma cells, and eosinophils (Figure, A and B). Occasional flame figures were identified (Figure, C). 

Wells syndrome. A, Histopathologic examination showed thickening of superficial capillaries and papillary fibrosis (H&E, original magnification ×4). B, There was a mixed interstitial and perivascular inflammatory infiltrate consisting of lymphocytes, histiocytes, plasma cells, and eosinophils (H&E, original magnification ×20). C, Occasional flame figures were identified (H&E, original magnification ×40).

Wells syndrome, also known as eosinophilic cellulitis, was first described in 1971 by Wells1 as a recurrent granulomatous dermatitis with eosinophilia. Rarely reported worldwide, this chronic relapsing condition is characterized by a pronounced eosinophilic infiltrate of the dermis resembling urticaria or cellulitis.2 The exact etiology has not been elucidated; however, links to certain medications, vaccines, exaggerated arthropod reactions, infections, and malignancies have been documented.3  

Wells syndrome is a diagnosis of exclusion and lacks a predictable dermatologic presentation, thereby mandating focused clinical follow-up as well as correlation with histopathology findings. Although the classic histologic hallmark of Wells syndrome is scattered flame figures, this finding is not specific and can be found in other hypereosinophilic conditions.2 Clinical manifestations most often consist of 2 distinct phases: an initial painful burning or pruritic sensation, followed by the development of erythematous and edematous dermal plaques that may heal with slight hyperpigmentation over 4 to 8 weeks. A case series of 19 patients demonstrated variants of Wells syndrome, with an annular granuloma-like appearance found primarily in adults and the signature plaque-type appearance predominating in children.4  

Acute urticaria is characterized by pruritic erythematous wheals secondary to a histamine-mediated response brought on by a variety of triggers, typically allergic and self-resolving within 24 hours. When such lesions last longer than 24 hours, biopsy should be performed to exclude urticarial vasculitis, which is characterized by a burning or painful sensation rather than pruritis, in addition to dermal neutrophilia and perivascular infiltrate on histology. Erythema migrans of Lyme disease begins at the site of a tick bite, evolving from a red macule to an expanding targetoid lesion and typically is not pruritic. Infectious cellulitis presents with warm, tender, and poorly defined erythematous patches; can progress rapidly; and is accompanied by systemic symptoms such as fevers, malaise, and lymphadenopathy.  

Best evidence favors the use of moderate- to high-dose corticosteroids as first-line treatment.5 The use of tumor necrosis factor blockers, various immunomodulating agents, and combination therapy with levocetirizine and hydroxyzine have demonstrated variable levels of efficacy, albeit often followed by high rates of relapse with drug discontinuation.6  

References
  1. Wells GC. Recurrent granulomatous dermatitis with eosinophilia. Trans St Johns Hosp Dermatol Soc. 1971;57:46-56. 
  2. Aberer W, Konrad K, Wolff K. Wells' syndrome is a distinctive disease entity and not a histologic diagnosis. J Am Acad Dermatol. 1988;18:105-114. 
  3. Kaufmann D, Pichler W, Beer JH. Severe episode of high fever with rash, lymphadenopathy, neutropenia, and eosinophilia after minocycline therapy for acne. Arch Intern Med. 1994;154:1983-1984. 
  4. Caputo R, Marzano AV, Vezzoli P, et al. Wells syndrome in adults and children: a report of 19 cases. Arch Dermatol. 2006;142:1157-1161. 
  5. Ferreli C, Pinna AL, Atzori L, et al. Eosinophilic cellulitis (Well's syndrome): a new case description. J Eur Acad Dermatol Venereol. 1999;13:41-45. 
  6. Cormerais M, Poizeau F, Darrieux L, et al. Wells' syndrome mimicking facial cellulitis: a report of two cases. Case Rep Dermatol. 2015;7:117-122.
References
  1. Wells GC. Recurrent granulomatous dermatitis with eosinophilia. Trans St Johns Hosp Dermatol Soc. 1971;57:46-56. 
  2. Aberer W, Konrad K, Wolff K. Wells' syndrome is a distinctive disease entity and not a histologic diagnosis. J Am Acad Dermatol. 1988;18:105-114. 
  3. Kaufmann D, Pichler W, Beer JH. Severe episode of high fever with rash, lymphadenopathy, neutropenia, and eosinophilia after minocycline therapy for acne. Arch Intern Med. 1994;154:1983-1984. 
  4. Caputo R, Marzano AV, Vezzoli P, et al. Wells syndrome in adults and children: a report of 19 cases. Arch Dermatol. 2006;142:1157-1161. 
  5. Ferreli C, Pinna AL, Atzori L, et al. Eosinophilic cellulitis (Well's syndrome): a new case description. J Eur Acad Dermatol Venereol. 1999;13:41-45. 
  6. Cormerais M, Poizeau F, Darrieux L, et al. Wells' syndrome mimicking facial cellulitis: a report of two cases. Case Rep Dermatol. 2015;7:117-122.
Issue
Cutis - 103(6)
Issue
Cutis - 103(6)
Page Number
E25-E27
Page Number
E25-E27
Publications
Publications
Topics
Article Type
Display Headline
Recurrent Pruritic Multifocal Erythematous Rash
Display Headline
Recurrent Pruritic Multifocal Erythematous Rash
Sections
Questionnaire Body

A 60-year-old man with a history of hyperlipidemia developed acute onset of an intensely pruritic and painful burning rash on the dorsal aspect of the left forearm of 8 days' duration. The patient described the rash as red and warm. It measured 2 cm at inception and peaked at 12 cm 6 months later when the patient presented. These symptoms resolved without therapeutic intervention.  

Over the ensuing 6 months, he experienced 13 self-limited episodes of erythematous indurated cutaneous streaks, usually with proximal migration on the arms along with involvement of the posterior thorax and right leg. Five months prior to the onset of the initial rash, the patient had discontinued ezetimibe to treat hyperlipidemia due to swelling of the lips and tongue. He also reported that he regularly hunted in upstate Pennsylvania but reported no history of arthropod or animal bites. The patient did not take prescription or over-the-counter medications, and he denied the presence of fever, night sweats, fatigue, adenopathy, anorexia, weight loss, diarrhea, joint pain or swelling, or illicit drug use. Lyme titers, complete blood cell count, erythrocyte sedimentation rate, and comprehensive metabolic panel were within reference range. A punch biopsy was performed. 

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 06/25/2019 - 10:30
Un-Gate On Date
Tue, 06/25/2019 - 10:30
Use ProPublica
CFC Schedule Remove Status
Tue, 06/25/2019 - 10:30
Hide sidebar & use full width
render the right sidebar.
Article PDF Media